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Abstract
Determining effective treatment strategies for life-threatening illnesses such as HIV is
a significant problem in clinical research. Currently, HIV treatment involves using
combinations of anti-HIV drugs to inhibit the formation of drug-resistant strains. From
a clinician’s perspective, this usually requires careful selection of drugs on the basis of an
individual’s immune responses at a particular time. As the number of drugs available for
treatment increases, this task becomes difficult. In a clinical trial setting, the task is even
more challenging since experience using new drugs is limited. For these reasons, this
research examines whether machine learning techniques, and more specifically batch
reinforcement learning, can be used for the purposes of determining the appropriate
treatment for an HIV-infected patient at a particular time. To do so, we consider using
fitted Q-iteration with extremely randomized trees, neural fitted Q-iteration and least
squares policy iteration. The use of batch reinforcement learning means that samples
of patient data are captured prior to learning to avoid imposing risks on a patient.
Because samples are re-used, these methods are data-efficient and particularly suited to
situations where large amounts of data are unavailable. We apply each of these learning
methods to both numerically generated and real data sets. Results from this research
highlight the advantages and disadvantages associated with each learning technique.
Real data testing has revealed that these batch reinforcement learning techniques have
the ability to suggest treatments that are reasonably consistent with those prescribed
by clinicians. The inclusion of additional state variables describing more about an
individual’s health could further improve this learning process. Ultimately, the use of
such reinforcement learning methods could be coupled with a clinician’s knowledge for
enhanced treatment design.
Keywords: Batch reinforcement learning, fitted Q-iteration, extremely randomized
trees, neural networks, least squares policy iteration, treatment simplification, HAART,
CD4+ T-lymphocyte, viral load.
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Chapter 1
Introduction
Determining suitable treatment regimens for life-threatening illnesses such as HIV, re-
mains one of the key aims of medical research. Typically, patients suffering from these
chronic illnesses are prescribed a series of treatments in order to maximize positive
outcomes. This usually involves selecting the optimal sequences of treatment or com-
binations of drugs for the patient over time and specifying the duration of individual
drug use. Because of the differences between individuals and their responses to therapy,
this task is difficult and ultimately relies on a clinician’s judgement to be performed.
In situations where newly developed drugs are used for treatment such as clinical trial
testing, the task becomes even more challenging since it is difficult to judge how an
individual will respond to a treatment with very little experience using the drug.
The Human Immunodeficiency Virus (HIV) is a retrovirus that potentially causes
Acquired Immune Deficiency Syndrome (AIDS). Having been identified 29 years ago,
HIV remains a worldwide threat after approximately 33 million people have been in-
fected with the virus (Douce et al., 2012). Once an HIV particle comes into contact with
and includes itself into certain cells of the immune system such as CD4+ T-lymphocytes,
a series of intracellular events occur that result in rapid viral reproduction, death of in-
fected immune cells and eventually a loss of immunity. To date, the only effective way
to treat HIV-infected individuals makes use of a combination of anti-HIV drugs in the
form of Highly Active Antiretroviral Therapy (HAART) (Adams et al., 2004). These
drugs operate by targeting various phases of the viral life cycle in an attempt to prevent
the virus from replicating. Because of advances made in these drug therapies since the
introduction of HAART in 1996, many individuals have been able to maintain viral
loads below detectable limits (< 40 copies/ml) and sustain high T-lymphocyte counts
for extended periods of time. Combination therapy is based on the premise that all
virions are not homogenous (Abadi et al., 2006). Instead, variants of the original virion
present in different proportions may exist within an HIV sufferer. Each of these vari-
ants has its own level of fitness that determines its chances of survival. While certain
strains may be resistant to a particular drug, it is less likely for a strain to be resistant
to a combination of two or more drugs. There are currently approximately 24 FDA-
approved anti-HIV drugs available (Smith, 2013). These drugs operate specifically by
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targeting the stages of viral entry, reverse transcription, integration of the viral genome
into the host cell and viral protein formation and maturation in the virus life cycle.
In particular, anti-HIV drugs may fall into one of five classes: (i) Non-nucleoside re-
verse transcriptase inhibitors (NNRTIs), (ii) nucleoside reverse transcriptase inhibitors
(NRTIs), (iii) protease inhibitors (PIs), (iv) entry inhibitors or (v) integrase inhibitors
(Stayley, 2012). Both categories of reverse transcriptase inhibitors prevent the conver-
sion of viral RNA into DNA to prevent the virus from successfully integrating into the
host’s genome (Stayley, 2012). Protease Inhibitors interfere with the protease enzyme
contained in an HIV particle; usually the protease enzyme dissects HIV proteins into
smaller pieces that can be used to create new virus particles. PIs thus prevent proper
cutting and structuring of these viral proteins (Stayley, 2012). In doing so, PIs effec-
tively reduce the number of infectious virus particles released by a cell. Entry inhibitors
prevent infection in cells of the immune system by preventing virus particles from bind-
ing to host cells. This binding process is crucial for the genetic material and enzymatic
content of a virus to be inserted into an immune cell and cause infection. Integrase
inhibitors interfere with the action of the integrase enzyme that enables viral DNA to
be incorporated into the host’s original genome (Stayley, 2012). Without this step, it
is impossible for the virus to replicate.
Despite the fact that HAART has helped manage the virus for many HIV-infected
individuals, it has not allowed for an outright cure. While eradication of HIV using
HAART may not be possible because of the manner in which the virus establishes
reservoirs within its host, there are a few other problems that have been encountered
with HAART use. Perhaps the most significant of these problems are the issues of poor
patient adherence to medication and the development of drug-resistant HIV strains in
certain situations. In addition, when antiretrovirals are used poorly, patients can expe-
rience many negative side effects, such as gastrointestinal disturbances, hepatotoxicity
and metabolic abnormalities (Abadi et al., 2006). As a result, it has become necessary
to determine how to schedule these drugs according to how a patient responds to their
treatment. To do so, a patient’s individual needs and immune responses need to be
taken into consideration. In a clinical trial setting, where newly developed anti-HIV
drugs are tested, this is even more important since experience using the drug is limited.
A strategy for sequencing anti-HIV drugs that gained popularity during earlier years
of HAART was the use of Structured Treatment Interruptions (STIs). During STIs,
patients were cycled on and off different drug therapies (Bonhoeffer et al., 2000). It
was initially thought that using STIs would prevent continued use of the same drugs
and hence inhibit the formation of drug-resistant strains. In addition, it was thought
that allowing patients periods of relief from treatment would elicit a stronger adaptive
immune response that would prove more effective once treatment was re-initiated. The
Strategies for Management of Antiretroviral Therapy (SMART) trial was conducted in
2001 to compare the use of continuous HAART and STIs amongst approximately 6 000
patients from 33 different countries worldwide (Lawrence & El-Sadr, 2006). Initially
the trial was aimed at collecting follow-up patient data for eight years unless a patient
progressed to AIDS, experienced very serious complications or died. Entry into the trial
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was eventually stopped in 2006 after several safety concerns were raised. Overall, it was
concluded that the use of STIs in HIV-infected individuals is inferior to continuous
HAART as patients experienced more complications, had poorer immune responses and
were more likely to progress to AIDS under STIs (Lawrence & El-Sadr, 2006).
A newer strategy for HAART has since emerged known as treatment simplifica-
tion. Treatment simplification is targeted specifically at improving patient adherence to
medication by either reducing the number of tablets a patient has to take or by attempt-
ing to mitigate the negative side effects experienced from the medications prescribed
(Pozniak, 2007). The former requires suitable drug combinations to be determined in
advance such that the drugs can be reformulated to reduce the number of pills a patient
is given. The latter requires proper assessment of the side effects experienced by an in-
dividual to determine which drugs are suitable for use and which are not. The difficulty
in combining different drugs into single tablets for a patient lies in the fact that not all
combinations of drugs are suitable for all patients. The introduction of new anti-HIV
drugs from advances in HAART research further complicates the process.
This research is aimed at determining suitable actions to take when treating an HIV-
infected individual based on their treatment history and their immune responses under
HAART. Specifically, we examine the use of reinforcement learning techniques to do so.
Reinforcement learning is a machine learning paradigm for choosing the best sequence
of actions in a system that changes over time (Sutton & Barto, 1998). In the context of
treatment design, reinforcement learning enables us to determine the long term effect of
a given treatment and hence determine an appropriate drug strategy over time. This is
particularly important since a treatment that produces favourable outcomes from short
term use is not necessarily guaranteed to do so in the long term. The hope is that using
machine learning techniques can provide some insight as to what combinations of drugs
are suitable for particular patients. In the context of clinical trials, this knowledge
can be combined with a clinician’s expertise to produce a judgement of how well a
particular drug works. A similar approach to design HIV treatment strategies has been
used by Ernst et al. (2006). Here, the authors propose the use of reinforcement learning
specifically for computing STI control strategies for simulated HIV patient data. It may
be possible to adapt the methods in this research to apply to treatment simplification.
The remainder of this thesis is structured as follows. Chapter 2 presents the bio-
logical background related to HIV. In particular, we examine the structure of an HI
virion; this viral structure is fundamental to understanding the manner in which HIV
is able to attack and weaken the immune system. We also present the detailed series
of events that occur once HIV infects an individual as well as existing strategies for
treating the virus. This includes the various classes of drugs that are currently in use
under HAART. The chapter concludes with a discussion on attempts at developing a
vaccine as a potential cure for HIV-infection and the implications this would have on the
global pandemic. Until a successful vaccine is developed, improved HAART strategies
are still necessary for managing the virus.
In Chapter 3, we present the reinforcement learning framework that forms the basis
of this thesis. We specifically focus on a class of learning techniques called batch rein-
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forcement learning methods that are suited to the problem of determining the suitable
course of action to take when treating an HIV patient. We also provide examples of
benchmark domains that have been used to compare the relative performances of each
learning technique under consideration.
In Chapter 4, we provide a detailed description of the specific aim of this research
and develop a series of research questions on which this work is focused. We also discuss
the methodology followed to complete this research which includes a description of how
we have formulated the HIV drug therapy problem as a Markov Decision Process.
We present, in condensed form, the main results obtained from applying the research
methodology from Chapter 4 to various data sets in Chapter 5. These results are
discussed with reference to the research questions posed. The overall outcomes of this
research and potential future investigations are summarized and presented in Chapter
6.
Chapter 2
Biological Background
2.1 Introduction
In this chapter, we explore the biology of the HI virus and its effect on the immune
system. Section 2.2 presents the basics of the immune system and how it works. We
focus specifically on the two major responses in place for acquired immunity namely,
humoral immunity and cell-mediated immunity. In Section 2.3, we discuss the struc-
tural details of HIV and its attack of the immune system, as well as differences between
strains of the virus. Section 2.4 presents the specifics of the immune response to HIV. In
particular, we examine the immunologic events occurring in the acute infection, clinical
latency and AIDS stages of the disease. In Section 2.5, the current antiretrovirals used
in treating HIV are introduced. These antiretrovirals are classified according to the
stages of HIV infection they inhibit. Section 2.6 explores early treatment strategies and
attempts at combatting HIV. Here, we focus on the introduction of HAART, and the
use of treatment interruptions as a method for stimulating an immune response among
HIV infected individuals. In Section 2.7 we examine a newer treatment simplification
approach to HAART which aims to reduce medication costs and improve patient ad-
herence. Finally, Section 2.8 concludes the chapter by discussing an entirely alternative
approach to HAART in the form of vaccine design as an attempt to eradicate the virus.
2.2 The immune system
In order to understand the process by which HIV infects the body, it is important to
have an understanding of the immune system. Any animal should be able to defend
itself against viruses, pathogens and bacteria that it may encounter during the course of
its life. For these reasons, two major defense mechanisms exist, namely innate immunity
and acquired immunity.
2.2.1 The innate immune system
The innate immune system is non-specific as to which organisms to defend the body
against and hence acts as its “first line of defense” against any invading pathogens
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(Mayer, 2011). That is, innate defenses usually respond quickly to a large variety of
micro-organisms, regardless of their specific nature or identity. Innate defenses are
usually in place from the time of birth and do not have to be developed. The innate
immune system consists of anatomic barriers formed by the skin and mucous mem-
branes, as well as a group of chemical and cellular defenses that protect against those
infectious agents that may bypass the external barriers (Mayer, 2011). Examples of
such internal cellular and chemical defenses include phagocytic cells, dendritic cells,
natural killer cells, inflammatory responses and antimicrobial proteins. Phagocytic cells
such as macrophages are responsible for attaching to and destroying pathogens through
enzymatic action (Campbell & Reece, 2005). They may also be responsible for pre-
senting pathogens to members of the acquired immune system. Natural killer cells are
responsible for the removal of virus-infected immune cells or cancer cells. This usually
occurs using a process called apoptosis whereby the killer cells release chemicals that
induce the death of an infected cell (Campbell & Reece, 2005). Antimicrobial proteins
operate in the innate defense by either attacking microbes directly or by hampering
their reproduction (Mayer, 2011).
Unlike the innate immune system, acquired immunity is adaptive and hence develops
only after exposure to foreign substances. These defenses are highly specific and are
hence slower in their response time in comparison to innate defenses (Campbell &
Reece, 2005). The major components of acquired immunity include antibodies and
lymphocytes although certain components of innate immunity may also function in the
acquired immune system. Next, we examine the details of acquired immunity.
2.2.2 The acquired immune system
When the first line of defense fails, it becomes necessary for the acquired immune system
to take control and eliminate any existing pathogens. Adaptive or acquired immunity is
a defense mechanism that is based on specific cellular targeting. While it is slower in its
response time than innate immunity, the adaptive response is more successful because
of its precision (Fisher, 2011). Specificity of acquired defenses is made possible by white
blood cells in the immune system. There are many different kinds of white blood cells
each with their own associated functions. The most important group of white blood
cells are referred to as lymphocytes and are responsible for recognizing and eliminating
any foreign substances or antigens that the body may encounter. This is done using a
range of distinct receptors. Lymphocytes originate from stem cells in the bone marrow
and may relocate to other parts of the body where they differentiate and mature (Fisher,
2011). There are three major groups of lymphocytes namely B-lymphocytes (B-cells), T-
lymphocytes (T-cells) and natural killer cells1. T-lymphocytes may further be classified
as either helper T-cells or cytotoxic T-cells. Helper T-cells may also be referred to as
CD4+ cells since they express the CD4 protein on their cell surface. Similarly, cytotoxic
T-cells may also be referred to as CD8+ cells.
B-cells remain in the bone marrow until they are mature. Upon maturation, they
1Natural killer cells also play a role in the innate immune system as discussed in Section 2.2.1.
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circulate through the bloodstream in search of antigens that they can recognize and
interact with. Once a B-cell attaches to an antigen, it begins replicating. The newly
formed B-cells can then differentiate into specialized B-cells known as either plasma
cells or memory B-cells. Plasma cells are responsible for the secretion of antibodies
that neutralize and defend against any pathogens that may be present in extracellular
fluid (Abbas & Lichtman, 2009). Memory B-cells are long-lived B-cells which may sur-
vive for several years after an infection (Fisher, 2011). These cells are responsible for
maintaining a record of which antigens the body has previously encountered. In doing
so, they are able to provide faster and more effective action against those antigens,
should they be re-encountered (Kumar et al., 2007). T-cells mature in the thymus into
effector cells before they circulate the lymph and blood in search of antigens (Abbas &
Lichtman, 2009). Effector cells can either assist other cells in counteracting antigens or
can directly kill infected cells, depending on their type (Fisher, 2011). Upon encoun-
tering an antigen, helper T-cells inform other cells such as macrophages, to assist in
eliminating the pathogens. Cytotoxic T-cells are specialized to secrete substances that
destroy the cells to which they have attached. This is particularly useful and important
for killing those cells that have been infected by a virus to prevent it from spreading fur-
ther. Like B-cells, certain helper and cytotoxic T-cells may differentiate into long-lived
T-cells that are able to respond rapidly to any secondary encounter with an antigen.
The acquired immune system may be divided into two parts: humoral immunity
and cell-mediated immunity. Humoral immunity is governed by B-cells (with assistance
from T-cells) and involves managing infectious agents that may be present in the blood
or tissues of the body (Fisher, 2011). Cell-mediated immunity is accomplished by T-
cells. Together, both parts of the immune system are able to provide a suitable immune
response to almost any antigen encountered. We examine each of these reactions in
turn.
The humoral immune response
The humoral immune response begins with the activation of a B-cell. There are two
ways in which a B-cell may be activated namely T-cell independent activation and T-
cell dependent activation (Fisher, 2011). During T-cell independent activation, antigens
interact with antigen receptor molecules on B-cells and activate the B-cells (Kumar
et al., 2007). This usually occurs for sugar or fat-based antigens. However, certain
protein antigens may not be able to bind to antigen receptors on B-cells. In these cases,
it may be necessary for helper T-cells to assist. Here, the B-cells typically ingest the
protein antigens, break them down and present the broken down peptides to the helper
T-cells to recognize. The helper T-cells then secrete chemical cytokines which assist in
activating the B-cells to elicit a suitable immune response (Kumar et al., 2007).
The activation of a B-cell is known as clonal selection. That is, once an antigen
activates a B-cell, it also activates all the B-cells that are capable of recognizing the same
antigen (known as a “clone”) (Fisher, 2011). Once the cells of a clone are activated,
they begin to proliferate by dividing. The division of activated cells is necessary to keep
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up with the rate at which the antigen proliferates. This process is referred to as clonal
expansion (Fisher, 2011).
Once the B-cell clones expand, the B-cells differentiate into plasma cells that produce
antibodies to combat the antigen. Each plasma cell secretes antibodies that are specific
to the antigen that was initially recognized during the activation step (Kumar et al.,
2007). These antibodies are capable of binding to the antigen which in turn, prevents
it from attaching to and infecting cells. Alternatively, the antibodies may mark a
particular antigen for destruction by members of the innate immune system such as
macrophages (Fisher, 2011). In this way, the antibodies are able to neutralize the effect
of any particular antigen. As the humoral immune response declines, some plasma cells
undergo ‘cell-suicide’ or apoptosis and die.
While the majority of the plasma cells die, certain plasma cells migrate to the bone
marrow where they continue to secrete antibodies for many years (Fisher, 2011). That
is, certain cells develop into memory B-cells following an infection. Should the body be
re-exposed to such an antigen, the memory cells will be able to respond more effectively
than naive lymphocytes.
Cell-mediated immune response
The second type of adaptive immune response is governed by T-cells. Unlike B-cells that
are able to recognize antigens with various chemical structures, T-cells are only able to
recognize particular fragments of peptides (Fisher, 2011). These peptide fragments are
exhibited by specialized molecules known as major histocompatibility complex (MHC)
molecules (Kumar et al., 2007). MHC is a protein-complex that is expressed on the
surfaces of cells of the body; that is, MHC molecules serve as identifiers for cells belong-
ing to the body. This is particularly important since it enables the body to distinguish
between ‘self’ and ‘non-self’, i.e. which substances belong to the body and which do not.
In general, MHC molecules function by exhibiting the antigens present in different cells
(Tamarkin, 2011). That is, when a cell comes into contact with a particular antigen, it
decides what course of action to take. The MHC molecules of the surface of that cell in
turn exhibit properties of the antigen on which the cell acts.
Consider the simple example of a virus invading cells of the stomach, as in gastroen-
teritis. Upon invasion, MHC molecules on the cells of the stomach display pieces of
the invading virus at the cell surfaces so that they may be recognized and acted on by
T-cells. This provides a scheme for labeling which cells should be acted on.
MHC molecules may be classified as either MHC I or MHC II molecules. MHC I
molecules are located on all the nucleated cells of the body and are responsible for
exhibiting those peptide antigens found within the cytoplasm of cells. MHC I molecules
are recognized by receptors on CD8+ cells (Fisher, 2011). In contrast, MHC II molecules
are located on antigen-presenting cells (APCs) and lymphocytes. These molecules are
responsible for displaying antigens from within the vesicles of the cells and are recognized
by receptors on CD4+ cells (Fisher, 2011).
There are five major steps in cell-mediated immunity: antigen presentation, anti-
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gen recognition and binding, differentiation and co-stimulation, antigen destruction and
elimination, and memory (Tamarkin, 2011). We examine each of these steps in turn.
1. Antigen presentation:
When a cell is recognized as ‘non-self’ because of its lack of MHC, immediate action
is required. This action is usually brought about by the innate immune system
through APCs such as macrophages or dendritic cells. Macrophages phagocytose
or ingest these foreign substances to eliminate any immediate threat they may
pose to the body. During this process, MHC molecules on the macrophage surfaces
exhibit fragments of the ingested antigen. The display of an antigen at the surface
of a cell is known as the “presentation” of an antigen (Tamarkin, 2011). It enables
the antigen to be seen safely and alerts the adaptive immune system to eliminate
any copies of the antigen that may be present.
2. Antigen recognition and binding:
APCs travel to the lymphoid tissue and exhibit antigens using MHC molecules on
their cell surfaces. T-cells with receptors that are specific to an antigen come into
contact with these APCs, bind with them and are activated (Fisher, 2011).
3. Differentiation and co-stimulation:
Once a clone of T-cells is activated, it expands by secreting a number of factors.
These factors are necessary for the growth, proliferation and differentiation of the
cells in the clone (Fisher, 2011). Certain members of the T-cell clone differentiate
into effector cells that release cytokines that perform different functions. The effect
of these cytokines is many-fold: cytokine secretion may increase phagocytotic
activity, encourage T-cell proliferation and differentiation and stimulate further
cytokine secretion (Tamarkin, 2011).
4. Antigen destruction and elimination:
The manner in which an antigen is destroyed is largely dependent on the kind of
cytokines released during co-stimulation. The kind of cytokines that are secreted
is in turn dependent on the kind of T-cells that have been produced following dif-
ferentiation. In general, there are 4 subsets of T-cells that may be produced during
differentiation: Th-1, Th-2, Th-172 and cytotoxic T-cells (Fisher, 2011). Th-1 and
Th-17 cells secrete factors that activate B-cells and stimulate macrophages whereas
Th-2 cells secrete special cytokines called interleukins (Kumar et al., 2007). These
interleukins are primarily responsible for antibody production and activation of
other white blood cells such as eosinophils. Eosinophils in turn, are capable of
destroying pathogens non-specifically. Cytotoxic T-cells produce a chemical called
perforin that destroys other T-cells that have already been infected by a pathogen
by inducing apoptosis (Tamarkin, 2011). In doing so, a given antigen or antigen-
infected cells may be destroyed and removed.
2Th-1, Th-2 and Th-17 are all types of helper T-cells.
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5. Memory:
Activation of T-cells stimulates the production of memory T-cells. These memory
T-cells, like memory B-cells, have the ability to survive for many years after an
infection and are capable of responding more effectively to a secondary encounter
of an antigen (Fisher, 2011).
Figure 2.1: Summary of humoral and cell-mediated immune responses (Carter, 2011).
Figure 2.1 presents a summary and comparison of both the humoral and cell-mediated
immune responses. The key stages of each response are illustrated.
Having examined the basic functioning of the immune system, we now explore the
structural details of HIV and the pathogenesis of the virus. In particular, the rest of the
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chapter presents some insights as to how the virus brings about changes in the human
body ultimately to override its defense system. We also look at existing treatment
strategies being implemented to control the spread of the virus.
2.3 The Human Immunodeficiency Virus
The Human Immunodeficiency Virus (HIV) is a lentivirus belonging to the group of
viruses known as retroviruses. Retroviruses are those viruses that characteristically
contain ribonucleic acid (RNA) as their genomic content. This is enclosed in a protein
capsid and lipid envelope (Mann & Ward, 2006).
2.3.1 Viral structure of HIV
Figure 2.2: Structure of the HI virion (Mann & Ward, 2006).
The HI virus is roughly spherical in shape and contains two copies of positive single-
stranded RNA. This RNA encodes for the virus’s nine genes. Differences in strains of
HIV may be attributed to differences in the genetic sequences encoded in the RNA.
The RNA is enclosed in a conical shaped capsid composed of a number of viral proteins
(Mann & Ward, 2006). The RNA is, in turn, tightly bound to a number of nucleo-
capsid proteins and enzymes that are necessary for the ultimate development of the
virion. These enzymes include reverse transcriptase, proteases, ribonuclease and inte-
grase (Chinen & Shearer, 2002). The capsid of the virion particle is surrounded by a
matrix of other viral proteins to ensure its integrity. Finally, a viral envelope composed
of two layers of phospholipids or fat molecules surrounds the entire virion. A number
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of glycoproteins, including gp120 and gp41, are embedded in this viral envelope (Chi-
nen & Shearer, 2002). These glycoproteins are critical for the correct fusion with, and
attachment to, target cells during the infectious cycle.
Figure 2.2 shows a diagram of the structure of an HI virion (Mann & Ward, 2006).
The bilayered viral envelope and glycoproteins on its surface are visible. The genetic
content and viral enzymes are also included.
2.3.2 The HIV replication cycle
Figure 2.3: The HIV replication cycle (Figure modified from Archer (2008)).
The HIV replication cycle consists of 6 different phases: binding and fusion, reverse
transcription, integration, transcription, assembly and budding. We examine each of
these stages in turn.
1. Binding and fusion:
HIV commences its life cycle through recognition of the viral glycoprotein gp120
with the CD4 cell surface molecule (Chinen & Shearer, 2002). That is, HIV
begins its life cycle with CD4 receptors on the surface of a CD4+ T-lymphocyte
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identifying the gp120 glycoprotein on the HI virus. Interaction of the proteins
causes the gp41 viral protein to interact with other molecules on the host’s plasma
membrane which in turn induces the viral envelope to fuse with the host cell
membrane (Chinen & Shearer, 2002). Following fusion, the virus releases its capsid
into the host cell. This includes all its genetic material, reverse transcriptase,
integrase and the viral proteins that initially comprised the virus.
2. Reverse transcription:
Entry of the capsid into the host cell results in the immediate release of the viral
genome and proteins into the cytoplasm. Reverse transcriptase converts the single-
stranded HIV RNA into complementary DNA (cDNA). In general, this process
integrates an incorrect nucleotide every 1 500 to 4 000 bases (Chinen & Shearer,
2002). This rapid rate of mutation may explain why the virus is more capable of
surviving and developing drug-resistant strains.
3. Integration:
Following the conversion of HIV RNA to cDNA, the viral cDNA is transported
across the nucleus where the HIV enzyme integrase masks the cDNA within the
host cell’s DNA. This enables the viral cDNA to integrate randomly into the host
genome. The newly integrated HIV DNA is called a provirus. In this form, the
provirus may remain inactive for a number of years, and may or may not produce
new copies of HIV.
4. Transcription:
After integration, certain transcription factors are able to trigger the host cell to
activate viral gene transcription (Chinen & Shearer, 2002). This is done using the
enzyme RNA polymerase to create multiple copies of the HIV genomic material.
In addition, a number of shorter strands of messenger RNA (mRNA) are produced.
The mRNA transcripts provide a blueprint for the HIV proteins that are to be
produced.
5. Assembly:
The components of the viral core are initially translated into pre-proteins each
consisting of a long chain of peptides. HIV protease mediates the cleavage of
these pre-proteins into smaller individual protein particles (Chinen & Shearer,
2002). These proteins move to the cell surface where they combine with the viral
RNA to form a new immature virus particle.
6. Budding:
The newly assembled virus particle is pushed out of the host cell. This process is
known as budding. At this stage, the virus merges with part of the cell’s outer
envelope. The cell envelope is embedded with glycoproteins. By including these
glycoproteins into the new virus particle, the virus is able to bind with and infect
other cells.
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Figure 2.3 is taken from Archer (2008). Here, the HIV cycle within a host cell is indicated
by the black arrows. The red and blue lines represent viral RNA and reverse-transcribed
cDNA respectively. Each of the phases of the viral replication cycle are shown.
This description is a gross simplification. The interested reader should refer to Cann &
Karn (1989) for a more detailed explanation.
2.3.3 Subtypes and strains of HIV
One of the characteristics of HIV that makes it particularly difficult to treat is its
ability to mutate. These mutations mean that the virus is highly variable and hence
different strains of HIV may exist even within an infected individual. There are two
phylogenetically distinct groups of HIV known as HIV-1 and HIV-2 (Archer, 2008).
Both forms of HIV are thought to originate from non-human primates: HIV-1 has
been linked to chimpanzees, whereas HIV-2 exhibits close similarity to viruses found in
sooty mangabeys (Cercocebus atys), a monkey species in west Africa. (Lihana et al.,
2012). Both groups of HIV have the same means of transmission and may result in
AIDS; however there are certain differences: HIV-2 is less easily transmitted, results
in a slower decline of T-cells and has a better clinical forecast (Sousa et al., 2002).
Within each group, different viral subtypes and strains may exist. The subtypes may
be associated with varying degrees of transmissibility and virulence (Chinen & Shearer,
2002). Strains of HIV-1 may be classified into three types: Majority (M), Outliers (O)
or New (N) (Archer, 2008).
Group M accounts for the majority of the global HIV pandemic and consists of
at least ten genetically distinct subtypes or clades of HIV-1 (Archer, 2008). These are
clades A through to K. Subtypes A, C, D and E predominate the developing world; clade
B is more common in Europe, America and Australia; clades H, K and J are limited to
parts of central Africa, west Africa and central America respectively (Chinen & Shearer,
2002). Many of the new strains do not have a high chance of survival individually but
rather as circulating recombinant forms (CRFs)3. These CRFs have arisen as a result
of genetic recombination between HIV strains in a particular host (Archer, 2008). The
overall outcome is a new hybrid virus that is capable of replicating and invading more
cells. It is this rapid ability of HIV-1 to recombine, mutate and generate extensive
diversity that results in continuous infection within a host in spite of the actions of the
immune system.
There are currently 8 known subtypes of HIV-2 (Santiago et al., 2005). These clades
are A through to H. Of these, only subtypes A and B are widespread. Clade A is common
in west Africa as well as Angola and parts of Brazil. Clade B is almost entirely confined
to west Africa. Subtypes C and D, E and F, and G and H are very rare and have been
found in parts of Liberia, Sierra Leone and the Ivory Coast respectively (Santiago et al.,
2005).
3Subtype I is a CRF that is a recombinant of subtypes A, G, H and K. As a result, it may not
necessarily be viewed as a subtype on its own.
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For purposes of this research, we focus entirely on the treatment of HIV-1. This is
largely because of its prevalence in South Africa and the data resources that we have
access to.
2.4 The immune response to HIV
Figure 2.4: Phases of acute HIV infection (Borrow, 2011).
Having examined basic immune functionality, we now examine the impact of HIV in-
fection on the immune system. The clinical course of HIV infection consists of three
stages namely, (i) acute/primary infection, (ii) clinical latency and (iii) AIDS (Pantaleo
& Fauci, 1996). Primary infection refers to the initial period of infection during which
viral RNA is detected by the immune system, and is characterized by a rapid rate of
viral reproduction; it ends once HIV antibodies begin developing several weeks after
infection (Mogensen et al., 2010). It is comprised of three phases: (i) the eclipse phase,
(ii) the viral expansion phase and (iii) the viral containment phase (McMichael et al.,
2010). The eclipse phase is a short period of time before viral RNA is detectable in the
blood plasma (McMichael et al., 2010). Typically, acute infection is characterized by a
rapid rate of viral reproduction. This occurs during the viral expansion phase. Because
of this, CD4+ counts can fall rapidly during this phase. Ultimately, the overall immune
response enables the virus level to be brought down to viral set point during which the
virus stabilizes and its rate of reproduction settles (Weber, 2001). At this point, the
CD4+ count may begin to increase. This is the viral containment phase (Borrow, 2011).
Figure 2.4 is taken from Borrow (2011). It presents a typical example of a patient’s
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viral load during the acute stage of infection. The peak viraemia is shown during the
viral expansion phase.
Clinical latency refers to the stage where despite being active, HIV reproduces at a
very low level. As a result, an HIV-infected individual may present few or no HIV-related
symptoms for many years during this phase. The clinical latency phase typically has a
variable length and depends largely on an individual’s immune responses and medication
used. Clinical latency may also be termed chronic HIV infection or asymptomatic HIV
infection. Once the clinical latency phase reaches completion, it is common for the viral
load to increase hence resulting in a depletion of CD4+ cells. If an individual’s CD4+
count falls below 200 cells/mm3, the individual is diagnosed with AIDS (Weber, 2001).
At this point, an individual’s immune system is severely compromised and becomes
particularly vulnerable to opportunistic infections. Next, we examine the clinical course
of HIV and the immunologic events associated with each stage of infection.
2.4.1 Innate immune response to primary HIV infection
The most basic innate defenses at the initial stages of HIV infection consist of epithelial
tissue and the mucosal membrane at the site of HIV transmission (Paranjape, 2005).
The mucosal epithelium is a physical barrier that provides protection against invading
virus particles. In addition, the presence of certain receptors at the epithelial layer
enables the early detection and recognition of molecular patterns specific to the virus
(Sivro et al., 2010). This detection promotes cytokine secretion which, in turn, ensures
the recruitment of other innate defenses such as dendritic cells and natural killer cells.
Following the entry of HIV into the bloodstream, adaptive immune responses may also
come into play. Dendritic cells, macrophages and other members of the innate immune
system may serve as APCs to induce adaptive immunity (Tamarkin, 2011). Geijtenbeek
et al. (2000) observe that dendritic cells also have the ability of transmitting the virus
without being infected through a process called transinfection. This particular situation
is an example of how HIV is able to use the immune defenses for its benefit. At this
stage, it is also common for natural killer cell counts to be elevated and for natural
killer cells to exhibit increased activity. This is largely because these cells have the
ability to kill any infected T-cells from the adaptive immune system, should the need
arise. As the acute phase of HIV infection progresses, dendritic cells are significantly
reduced (McMichael et al., 2010). Possible reasons for this include migration of activated
dendritic cells to the lymph nodes or dendritic apoptosis.
2.4.2 T-cell and antibody response to primary HIV infection
The acute phase of HIV infection is typically characterized by a rapid rate of viral
replication and hence high viral load. As a result, HIV-specific cell-mediated responses
can be detected at the extremely early stages of primary infection (Pantaleo & Fauci,
1996). That is, the acute phase may be dominated by large increases in the number of
CD8+ T-lymphocytes in order to control the spread of infection. A spike in the CD8+
T-cell response usually causes the virus to undergo mutation making it more difficult
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to control (McMichael et al., 2010). This response is usually accompanied by a marked
decline in the number of circulating helper T-cells corresponding to the peak in viraemia
(Paranjape, 2005). During the entire infection process, HIV depletes the immune sys-
tem of memory T-cells however, the exact mechanism(s) by which HIV kills T-cells is
controversial. It is thought that a combination of direct killing of infected cells and
indirect killing of uninfected cells contributes to the weakening of the immune response.
Indirect killing may be made possible by the participation of certain HIV viral proteins
in apoptotic pathways. That is, certain HIV viral proteins may engage in activities
that induce apoptosis in T-cells (Streeck & Nixon, 2010). In other instances, indirect
T-cell destruction involves damaging the cell membrane through continual budding of
the virus. This procedure is believed to increase cell permeability thereby promoting
the entry of more pathogens into the cell, and ultimately contributing to cell death
(Paranjape, 2005).
The initial spike in viraemia eventually ends with a decrease in viral RNA levels as
a result of CD8+ cells targeting the HIV. Once this occurs, the RNA levels establish
a viral set point. It is widely believed that CD8+ T-cells are critically important for
the maintenance of this viral set point. Pantaleo & Fauci (1996) observe that patients
with a stronger early cytotoxic T-cell response experience lower viral loads over longer
periods resulting in slower progression of the virus.
2.4.3 Immunologic events during clinical latency and AIDS
Clinical latency during HIV is used to describe the generally asymptomatic stage of
HIV infection during which viral replication slows down considerably. One possible
explanation for the decline in the viral load during this phase is provided by Siliciano
& Greene (2011): it is likely that during the clinical latency phase, certain actively
infected CD4+ T-lymphocytes survive long enough to revert back to their previously
inactive state. In this state, any gene expression of the virus is terminated and is hence
unaffected by any immune responses or antiretroviral drugs. At the end of the clinical
latency phase, these T-cells can be reactivated and latency can be reversed (Siliciano &
Greene, 2011). In this way, latency reservoirs enable viral copies to begin re-circulating.
If this is true, HIV latency enables the virus to exploit the most critical aspect of
immunity namely the memory in long-lived T-lymphocytes. The implications of this
are tremendous for any attempts to eradicate the virus.
Innate immune activation during the chronic phase of HIV is thought to be a signif-
icant contributor to the destruction of the immune system (Sivro et al., 2010). Many
innate responses that serve as protective mechanisms during acute infection can be
harmful in the chronic phase where they may be ‘too little too late’. A particular ex-
ample of this is the secretion of a chemical called interferon by dendritic cells; these
secretions have deleterious effects as they induce cell death in both infected and unin-
fected T-lymphocytes - an undesirable response at this stage, that ultimately leads to
a state of immune deficiency (Boasso & Shearer, 2008).
As the immune system weakens an individual increasingly becomes at risk of devel-
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oping opportunistic infections or cancers, resulting in the diagnosis of AIDS.
The explanation provided in this section has been simplified considerably. The reader
should refer to Walker & McMichael (2012) and Swanstrom & Coffin (2012) for a more
rigorous treatment of the immune response to HIV.
2.5 Drug therapy for management of HIV
Currently a variety of HIV treatments exist with over 20 FDA-approved anti-HIV drugs
available for use. These drugs when combined are termed antiretrovirals (ARVs). Typ-
ically, ARV drugs function by inhibiting certain phases of the HIV life cycle in an
attempt to stop replication and further spread. There are five main classes of ARVs: (i)
Non-nucleoside reverse transcriptase inhibitors (NNRTIs), (ii) Nucleoside reverse tran-
scriptase inhibitors (NRTIs), (iii) Protease inhibitors (PIs), (iv) Fusion inhibitors, and
(v) Integrase inhibitors (Stayley, 2012). As attempts have also been made to reduce the
number of tablets a patient has to take daily, several single tablet regimens exist that
combine drugs from these classes together in a single dose.4 We examine each of the
drug classes in terms of their functionality.
2.5.1 Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Name Drug Combination Dosage
Edurant rilpivirine hydrochloride
(RPV)
One 25mg tablet daily.
Intelence etravirine (ETV) One 200mg tablet daily, or one
100mg tablets twice daily.
Rescriptor delaviridine (DLV) Two 200mg tablets three times
a day.
Sustiva efavirenz (EFV) One 600mg tablet daily, or
three 200mg daily.
Viramune nevirapine (NVP) One 400 mg tablet once a day.
Table 2.1: List of currently approved NNRTIs with their dosages (Smith, 2013).
Enzymes are typically specific in terms of the substrates they interact with and the
reactions that they catalyze. Complementarity of the shape of the enzyme and the
shape of the substrate is partly responsible for this specificity. NNRTIs operate by
binding to the reverse transcriptase enzyme and inducing conformational changes in
the structure of the enzyme (Stayley, 2012). This, in turn, affects the catalytic ability
of the enzyme and inhibits the transcription of viral RNA. The implications are that
4While these single tablet regimens are designed to make HIV treatment easier, many patients in
South Africa still do not have access to such medication.
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viral RNA cannot be reverse transcribed into cDNA correctly, and integration of the
virus into the host genome is not possible.
Table 2.1 lists the major NNRTIs as of 2013 and their daily dosages.
2.5.2 Nucleoside reverse transcriptase inhibitors (NRTIs)
Name Drug Combination Dosage
Combivir lamivudine/zidovudine
(3TC/AZT)
One tablet (150mg lamivu-
dine/300mg zidovudine), twice
daily.
Emtriva emtricitabine (FTC) One 200mg tablet daily.
Epivir lamivudine (3TC) One 300mg tablet daily, or one
150mg twice daily.
Epzicom abacavir/lamivudine
(ABC/3TC)
One tablet (600mg aba-
cavir/300mg lamivudine)
daily
Retrovir zidovudine (AZT) One 300mg tablet, twice daily.
Trizivir abacavir/lamivudine/
zidovudine
(ABC/3TC/AZT)
One tablet (300mg aba-
cavir/150mg lamivu-
dine/300mg zidovudine),
twice daily.
Truvada emtricitabine/tenofovir
disoproxil fumarate
(FTC/tdf)
One 300mg tablet daily.
Videx EC didanosine (ddl) One 400mg capsule daily.
Viread tenofovir disoproxil fu-
marate (tdf)
One 300mg tablet daily.
Zerit stavudine (d4T) One 30mg capsule, twice daily.
Ziagen abacavir sulphate (ABC) One 300mg tablet, twice daily.
Table 2.2: List of currently approved NRTIs with their dosages (Smith, 2013).
NRTIs may also be referred to as nucleotide reverse transcriptase inhibitors, nucleotide
analogues or nucleoside analogues which inhibit the reverse transcription of viral RNA
into cDNA (Stayley, 2012). NRTIs do so by incorporating faulty nucleotides into the re-
verse transcription process. The implications are that the new DNA is not constructed
correctly. In this way, the genetic content of HIV cannot integrate with the genetic
material already in the host cell thereby preventing the cell from reproducing the virus.
Generally nucleoside analogues and nucleotide analogues have small structural differ-
ences but perform in much the same way: nucleoside analogues need to undergo an
extra phosphorylation step in order to be activated for use; nucleotide analogues do not
need this step (Stayley, 2012).
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Table 2.2 lists the major NRTIs as of 2013 and their dosages per day.
2.5.3 Protease inhibitors (PIs)
Name Drug Combination Dosage
Aptivus tipranavir (TPV) Two 250mg capsules with two
100mg tablets ritonavir, twice
daily.
Crixivan indinavir (IDV) Two 400mg capsules every
eight hours, or two 400mg
capsules with 100mg ritonavir
twice a day.
Invirase saquinavir (SQV) Two 500mg tablets with 100mg
ritonavir twice daily.
Kaletra lopinavir/ritonavir
(LPV/r)
Four tablets (200mg
lopinavir/50mg ritonavir)
once daily, or two (200mg
lopinavir/50mg ritonavir),
twice daily.
Lexiva fosamprenavir calcium
(FPV)
Two 700mg tablets with 100mg
ritonavir daily.
Norvir ritonavir (r) 100-400mg dosed once or twice
daily with another PI.
Prezista darunavir (DRV) One 800mg tablet or two
400mg tablets with 100mg ri-
tonavir daily.
Reyataz atazanavir sulphate
(ATV)
One 300mg capsule and 100mg
ritonavir daily.
Viracept nelfinavir (NFV) Two 625mg tablets, twice daily.
Table 2.3: List of currently approved PIs with their dosages (Smith, 2013).
PIs prevent the process of viral replication by binding to viral proteases that are criti-
cal for the production of new virus particles during the budding phase. In particular,
these drugs operate by binding selectively to HIV-1 protease thereby blocking the cleav-
age process of many of the protein precursors needed for the formation of new virions
(Stayley, 2012). The majority of virions produced in the presence of PIs contain major
defects and cannot cause further infection.
The major concern with use of PIs is their specificity in terms of their target. That
is, PIs are very specific about the viral proteases they interact with. Because of this
specificity, it is common for patients to develop drug-resistant strains of HIV that are no
longer affected by PIs. In order to reduce this risk, PIs are most often used in conjunction
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with other anti-HIV drugs, each targeting a different aspect of viral replication.
Table 2.3 provides a summary of the current PIs in use and their dosages.
2.5.4 Fusion inhibitors
Fusion inhibitors, also termed entry inhibitors, interfere with the ability of HIV to bind
with, fuse and enter healthy host cells in the body. This is the key difference between
entry inhibitors and other anti-HIV drugs that are active only after HIV has infected a
cell (Stayley, 2012). The process by which fusion inhibitors prevent HIV from entering
immune cells involves attaching to the gp41 and gp120 proteins at the surface of CD4+
cells or proteins on the surface of the HIV virion. If entry inhibitors are fully functional,
they can be successful in preventing the binding and entry of HIV to immune cells.
Patients who have developed resistance to other antiretroviral drugs could benefit
from using fusion inhibitor drugs.
Table 2.4 provides a list of the current fusion inhibitor drugs and their dosages.
Name Drug Combination Dosage
Fuzeon enfuvirtide (ENF or T-
20)
90mg subcutaneous injection
twice daily.
Selzentry maraviroc (MVC) 150mg, 300mg or 600mg twice
daily, depending on other med-
ication used.
Table 2.4: List of currently approved fusion/entry inhibitors with their dosages (Smith,
2013).
2.5.5 Integrase inhibitors
In order for HIV to take control of a host cell’s machinery to produce more virions, viral
DNA must be incorporated with the cell’s original DNA. This is the integration step of
viral replication. Integrase inhibitors operate by inhibiting the action of the integrase
enzyme during this phase of viral replication (Stayley, 2012). In doing so, integrase
inhibitors may block the formation of a provirus.
Table 2.5 lists the integrase inhibitors in use in 2013 and their dosages.
Name Drug Combination Dosage
Isentress raltegravir (RAL) One 400mg tablet twice daily.
elvitegravir elvitegravir (EVG) 150mg once a day with 150mg
cobicistat.
dolutegravir dolutegravir (DTG) One 50mg tablet daily.
Table 2.5: List of currently approved integrase inhibitors with their dosages (Smith,
2013).
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Having examined the various kinds of drugs available for treatment of HIV, we now focus
on previous attempts at combating the virus and the outcomes of these approaches.
2.6 Initial treatment strategies: HAART and STIs
Conventional treatment for HIV patients makes use of highly active anti-retroviral ther-
apy (HAART) (Bartlett, 2006). This treatment consists of using a mixture of multiple
drugs, typically from more than one class, and is hence commonly referred to as com-
bination therapy. The overall aim of HAART is to help patients maintain functionality
of the immune system, decrease their overall viral load, and reduce risk of those oppor-
tunistic infections that usually result in death. Combination therapy is based on the
premise that all virions are not homogeneous (Adams et al., 2004). Different variants
may be present in varying proportions. Each variant has its own corresponding fitness
which determines its chances of survival. While certain strains may be resistant to a
particular drug, it is less likely for a strain to be resistant to two or more drugs.
The advent of HAART can be dated to the 11th International Conference on AIDS
at British Columbia, Vancouver, during July 1996 (Bartlett, 2006). Findings at this
conference indicated that an HIV-infected individual produces on average 10 billion
virions per day (Bartlett, 2006). This conference was followed by subsequent publica-
tions in The New England Journal of Medicine by Gulick et al. (1997) and Hammer
et al. (1997) in which the benefits of using a cocktail of three drugs (also known as triple
drug therapy) were highlighted. The concept of combination therapy has since been in-
corporated into most hospital treatment plans and has been of considerable importance
in the progression of combatting HIV. Typical combinations of ARVs in HAART in-
clude using 2 NRTIs in conjunction with 1 PI or using 2 NRTIs with 1 NNRTI, although
new combinations are emerging since the introduction of entry inhibitors (Gulick et al.,
1997).
2.6.1 Rationale for intermittent therapy
Despite the general worldwide success in managing the virus through HAART, concerns
about the side-effects and costs of continual drug therapy as well as the possibility
of developing drug resistance led to the design of intermittent therapy as a possible
means of combatting these concerns (Lawrence & El-Sadr, 2006). Structured Treatment
Interruptions (STIs) were an experimental approach designed specifically with the goals
of (i) boosting the immune response in both the acute and chronic phases of infection,
(ii) improving adherence to treatment (ii) regaining drug-sensitive forms of the virus
in patients that had previously experienced virologic failure and (iii) reducing drug-
toxicity levels and mitigating the negative side effects of ARV therapy. In patients
suffering acute HIV infection, interruptions were thought to stimulate innate immune
responses to antigens; in patients with chronic HIV that had developed drug-resistant
viral types, interruptions were thought to allow drug-sensitive viral types to reappear.
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2.6.2 Assessing the efficacy of treatment interruption
Many studies have been conducted in order to investigate the impact of treatment
interruption on managing HIV. The Stacatto trial was one such study in which 430
candidates received randomized treatment either in the form of continuous therapy or
in the form of intermittent therapy (Lawrence & El-Sadr, 2006). The patients in the
group receiving intermittent therapy were only given treatment if their CD4+ count was
below the 350 cells/mm3 mark. The major results from this trial were that adverse side
effects such as diarrhea, were experienced more frequently by the patients undergoing
continuous therapy, and a 62% reduction in ARV costs was reported for patients using
treatment interruption (Lawrence & El-Sadr, 2006). While the results of this study
were encouraging for treatment interruption, the study gave no indication of the clinical
efficacy of each procedure.
Another such study more focused on the value of each treatment strategy, was the
ANRS 1260 Trivican trial (Lawrence & El-Sadr, 2006). 326 patients with CD4+ counts
over 350 cells/mm3 received randomized ARV therapy in the form of either continuous
therapy or one of two treatment interruption strategies: (i) CD4+ count guided or (ii)
time guided. In CD4+ count guided therapy, patients stopped anti-HIV drugs when their
T-lymphocyte counts were over 350 cells/mm3 and re-started drug therapy when cell
counts fell below 250 cells/mm3 (Lawrence & El-Sadr, 2006). In time-guided therapy,
patients were cycled on and off drug therapy every two months. Results from this trial
indicated that patients under CD4+ count guided intermittent therapy were particularly
at risk of further disease progression.
2.6.3 Controversy following the SMART study
Perhaps the most significant study comparing intermittent therapy to continuous HAART,
is the SMART trial. The SMART trial is the largest treatment interruption clinical trial
to date (Lawrence & El-Sadr, 2006). Pre-requisites for entry into the trial were a CD4+
count above 350 cells/mm3. Approximately 6 000 patients from 33 countries and over
318 sites were recruited providing several years of followup data (Lawrence & El-Sadr,
2006). Each patient was randomly assigned a treatment strategy i.e. continuous ther-
apy or treatment interruption. The aim of intermittent therapy was to keep candidates
off ARVs until CD4+ counts were below the 250 cells/mm3 mark and then continue
treatment until cell counts increased above 350 cells/mm3. Patients were removed from
the trial in certain special cases such as if HIV had progressed to AIDS, death or other
serious complications. Comparisons concerning the side effects, complications, drug re-
sistance, cost, patient adherence and overall clinical efficacy of each strategy were made
(Lawrence & El-Sadr, 2006).
Results from the SMART study showed significant differences between both types
of treatment particularly concerning death among the groups. A total of 117 AIDS or
death occurrences were reported in the group of patients using STIs; 47 such events were
reported in the continuous HAART group (Lawrence & El-Sadr, 2006). In addition, a
lower incidence of cardiovascular, hepatic and renal complications was reported among
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patients belonging to the continuous therapy group. Investigators from the SMART
trial eventually deemed treatment interruption strategies as risky for patients suffering
HIV with few benefits. Dr Wafaa El-Sadr from the SMART trial concluded: “Episodic
use of antiretroviral therapy based on CD4+ cell counts, as utilized in the SMART
study design, is inferior to continuous antiretroviral therapy for the management of
antiretroviral-experienced patients,” (Lawrence & El-Sadr, 2006).
2.7 A treatment simplification approach to HAART
Assuring good patient adherence to HAART may require treatment regimens to be sim-
plified. Among other techniques, this treatment simplification may be in the form of
reducing the number of pills a patient needs to take, or reducing use of drugs from a
particular class according to their relative toxicities (Pozniak, 2007). The overall ben-
efits of simplifying HAART thus include improving adherence, mitigating negative side
effects, and reducing the costs of medication. Currently, there are two popular methods
of treatment simplification that have been investigated: (i) PI-sparing approaches and
(ii) PI-boosting approaches (Pozniak, 2007). We examine both of these techniques in
turn.
2.7.1 PI-sparing approaches for treatment simplification
The aim of PI-sparing approaches for treatment simplification is to sufficiently suppress
the virus using fewer pills. PIs are known to have several side effects including gastroin-
testinal disturbances, lipohypertrophy, and cardiovascular problems. PI-sparing drug
combinations hope to reduce such side effects (Pozniak, 2007). Since the introduction
of NNRTIs, there have been a number of clinical trials in which PIs were substituted
with this class of drug in the hope of reducing toxicity levels and improving quality of
life for HIV infected individuals. One such trial used 498 PI-treated patients who were
randomized to substitute their PI with one of two NNRTIs namely EFV, NVP or the
NRTI ABC. It was observed that after 48 weeks viral loads were lower in patients using
NNRTIs and NRTIs in place of PIs, but negative side effects were more frequent: 84%
of patients using PI-free therapy maintained viral suppression in comparison with 73%
of patients using PI-inclusive strategies (Pozniak, 2007).
2.7.2 PI-boosting approaches for treatment simplification
Reduced-pill regimens are being investigated as a means of maintaining viral suppres-
sion in HIV patients. Certain ARV drugs have been re-formulated for once-daily use
(Pozniak, 2007). In particular, the NRTIs ddl, FTC, 3TC and tdf and boosted PIs, ATV
and fosamprenavir, are currently used in this form. In addition, certain drugs have been
coupled with others; examples of this include lopinavir which is now used only in con-
junction with ritonavir. Use of a single boosted PI is thought to have the associated
advantages of reducing lactic acidosis, mitochondrial malfunctioning and lipoatrophy
among others (Pozniak, 2007).
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Table 2.6 provides a list of the current single tablet regimens in use.
Name Drug Combination Dosage
Atripla efavirenz/emtricitabine/
tenofovir disoproxil
fumarate (EFV/FTC/tdf)
One tablet (600mg efavirenz/
200mg emtricitabine/300mg
tenofovir df) daily.
Complera rilpivirine/emtricitabine/
tenofovir disoproxil fu-
marate (RPV/FTC/tdf)
One tablet (25mg rilpivirine
/200mg emtricitabine/300mg
tenofovir df) daily.
Stribild elvitegravir/cobicistat/
emtricitabine/tenofovir
disoproxil fumarate
(EVG/COBI/FTC/tdf)
One tablet (150mg
elvitegravir/150mg co-
bicistat/200mg emtric-
itabine/300mg tenofovir
DF) daily.
“572-Trii” dolutegravir/abacavir/
lamivudine
(DTG/ABC/3TC)
One tablet (50mg dolute-
gravir/600mg abacavir/300mg
lamivudine) once a day for first
time HIV therapy patients; two
times a day for patients who
have developed resistance to
Isentress and elvitegravir.
cobicistat COBI 150mg daily. Cobicistat is not
an HIV drug, but is used to in-
crease the levels of elvitegravir
and HIV protease inhibitors.
Table 2.6: List of current single tablet regimens and the contents of each tablet.
2.7.3 Implications for HAART
While treatment simplification regimens for HAART aim to reduce pill burden in pa-
tients and mitigate negative side-effects, using such strategies has a number of implica-
tions.
1. Suitable drug combinations for a reduction in pill burden need to be determined.
2. Typically this would involve a series of clinical trials to be conducted to determine
the safety of certain combinations.
3. Clinical trials are expensive to conduct and are usually conducted over a long
period of time.
For these reasons, it may be necessary to couple clinical trials with other methods of
predicting the effects of certain drug combinations on the immune system.
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2.8 Exploring the alternatives: vaccine development
Despite advances made in developing antiretrovirals suited to suppressing HIV infection
and preventing its progression to AIDS, an effective vaccine for eradicating the virus has
not been established. Developing a successful HIV vaccine that is capable of inactivating
the virus as a whole, is perhaps one of the most significant global health challenges to
date. Scientists have attempted developing classic prophylactic vaccines, as used for
polio and measles, to combat HIV infection. These vaccines make use of inactive or
live attenuated virus particles in which the major viral genes contain deletions (Lai &
Heeney, 2012). Both types of prophylactic vaccines have failed since inactive HI virus
particles are poorly immunogenic and introducing live attenuated virus particles into
a system has proven to increase chances of HIV progressing to AIDS (Lai & Heeney,
2012).
Unlike the polio virus or measles, HIV has two distinguishing features which have
complicated the process of discovering a suitable vaccine. The first is that HIV uses
a DNA intermediate, specifically a provirus, to establish itself and replicate (Lai &
Heeney, 2012). In this form, the virus can integrate with a host’s genome and remain
inactive for years until an unknown series of events triggers the onset of viral replication.
Once replication begins, the virus starts invading T-cells and other APCs. The most
severe implication is that the virus establishes reservoirs which are used to continuously
attack and invade more immune cells. The second feature that distinguishes HIV from
similar viruses is its ability to mutate at a high frequency. The mutations produced are
a direct result of a lack of proofreading mechanism incorporated into the reverse tran-
scriptase enzyme. Traditionally, enzymes that catalyze such reactions have a built-in
mechanism of correcting any erroneous nucleotide bases that are transcribed to prevent
the occurrence of mutations; the HIV reverse transcriptase enzyme does not have this.
The implications of this are significant: the cDNA that is transcribed contains many
mutations resulting in altered viral protein production. This variability of HIV makes
developing a protective vaccine extremely difficult since such a vaccine would have to
be able to provide protection against all viral strains.
Newer strategies for vaccine development have differed according to the ways in
which they seek to combat HIV. The majority of these strategies can be broadly clas-
sified into three categories. The first category is a set of vaccines that have aimed
to utilize a class of antibodies termed broadly neutralizing antibodies to combat the
spread of the virus. These antibodies, unlike traditional antibodies, are not specific in
the antigens they can neutralize; instead they can neutralize a broad spectrum of viral
variants by attaching to regions of antigens that do not change upon viral mutation.
The discovery of such antibodies could prove extremely important for determining a
suitable means of combatting the virus in the future. The second set of vaccines are
aimed at using certain properties of T-lymphocytes to sustain an adequate immune
response in situations where antigens are not capable of inducing broadly neutralizing
antibody responses (Lai & Heeney, 2012). The third set of vaccines are based on using
gene therapy to produce an immunization against the virus. Briefly, gene therapy steps
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away from developing a T-cell or B-cell based vaccine for HIV-1. Instead, the focus is
on targeting the virus using intracellular immunization (Lai & Heeney, 2012). The goal
of intracellular immunization is to prevent viral replication by modifying target cells of
the immune system to express antiviral genes. Gene therapy vaccination would involve
collecting T-lymphocytes, genetically modifying each cell to include an antiviral gene,
and injecting the infusion back into a HIV-infected individual (von Laer & Brandenburg,
2001).
Vaccine research is typically a lengthy process that is conducted in phases. At
each phase of a clinical trial, the candidate vaccines are tested on human volunteers.
Despite scientists exploring numerous strategies for HIV vaccine development, only three
potential candidate vaccines have completed large-scale clinical trial testing to date.
These are the AIDSVAX by VaxGen, STEP by Merck and the RV144 which combines
two previous vaccines that have failed individually. The AIDSVAX was an experimental
prophylactic HIV vaccine that was initially developed by Genentech in 1991 and tested
later by VaxGen (Billich, 2001). At its core, the vaccine made use of proteins that are
recombinant forms of the surface protein gp120 from two types of HIV. In particular, the
primary goal of the AIDSVAX was to induce a broadly neutralizing antibody response
which could potentially provide protection against infection (Billich, 2001). Clinical trial
testing for the vaccine began in 1998 across the United States with 5403 participants, the
majority of whom were homosexual men. Phase II of the trial started in 1999 in Thailand
and reached completion in 2003. Results from the clinical trial showed that neither
version of the vaccine succeeded in preventing HIV infection (Lai & Heeney, 2012). The
STEP vaccine, also known as Merck’s V520-023, was a T-cell based vaccine containing a
weakened adenovirus such as a common cold virus, in addition to three HIV-1 subtype
B genes (Sekaly, 2008). The vaccine was aimed at targeting cell-mediated responses.
These responses are believed to be particularly important in the early stages of viral
infection. It was thought that the addition of an adenovirus could elicit stronger cell-
mediated responses which could in turn be used to eliminate HIV-infection. The vaccine
was tested on 3 000 participants until September 2007 where use was discontinued
following substantial evidence that the vaccine failed to provide protection against HIV
and potentially increased chances of developing infection (Lai & Heeney, 2012). The
closest attempt thus far at developing a suitable vaccine for HIV is the RV144 vaccine
from a Thai trial in 2009. This vaccine was based on combining two previously failed
vaccine attempts to form a new vaccine. In particular, a bird virus containing three HIV
genes was combined with a modified version of the AIDSVAX vaccine in the hope of
eliciting a boosted immune response (Rerks-Ngarm et al., 2009). The vaccine was tested
on 16 402 individuals making the trial the largest clinical trial for HIV vaccination to
date (Rerks-Ngarm et al., 2009). It was initially thought that such a vaccine would
be unsuccessful since both components of the vaccine had failed individually. However,
results from the trial indicated otherwise: overall the vaccine combination proved to be
somewhat effective and reduced the risk of HIV infection among participants by 31%
(Rerks-Ngarm et al., 2009). While this figure is too small for a feasible vaccine, it is
still significant.
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The expansion of the HIV pandemic has highlighted the need for a suitable HIV
vaccine to be developed in the future. A number of scientific advances have been made
in the field of HIV vaccine development in recent years. The majority of these advances
have been based on having a better understanding of the viral structure of HIV and the
human immune response to the virus. It is likely that future success in this field will come
from a vaccine that is able to elicit an immune response consisting of both neutralizing
antibodies that target regions of the virus that are conserved during mutation, as well
as cytotoxic T-cells that target a variety of antigens. Overall, progress in the field will
require continued commitment of researchers as well as adequate government support.
2.9 Conclusion
This chapter provided an overview of the key role players in the immune system and how
they interact during HIV interaction. The major components of the acquired immune
system are particularly important for keeping the virus under control and are usually
good indicators of a patient’s state of health. These members of the acquired immune
system may be used to model the HIV drug scheduling problem as a reinforcement
learning task which we explore in Chapters 3 and 4. We also presented an overview of
the different classes of drugs that are currently in use for HIV treatment and discussed
treatment simplification as a strategy in place to reduce pill burden and improve ad-
herence among HIV sufferers. Treatment simplification strategies require determining
suitable drug combinations usually through a clinical trial basis. Coupling these studies
with the batch reinforcement learning techniques that we examine in Chapter 3 could
provide a reasonable basis for solving the drug scheduling problem. The next chapter
discusses the reinforcement learning paradigm which has been used to model the HIV
drug scheduling task in this research.
Chapter 3
Reinforcement Learning
Background
3.1 Introduction
In this chapter, we discuss the reinforcement learning framework that forms the basis of
this research. Section 3.2 presents the specifics of the reinforcement learning paradigm in
terms of how an agent and environment interact to achieve a specific goal. In particular,
we examine how a reinforcement learning problem can be formulated in terms of a
Markov decision process and introduce the concept of a value function to assess the
overall performance of the agent relative to the environment at a particular time. Section
3.3 explores how basic value iteration may be performed when the dynamics of agent-
environment interaction are available. In Section 3.4 we extend this to the model-free
case by examining the online Q-learning algorithm that forms the basis of the batch
reinforcement learning techniques we use throughout this research. The subsequent
Sections 3.5 - 3.9 discuss the need for batch reinforcement learning methods within
the context of traditional reinforcement learning and present the various techniques
being used in this research namely fitted Q-iteration, neural fitted Q-iteration and
least squares policy iteration. In particular, we focus on the specifics of the function
approximation techniques employed by each of the algorithms by discussing extremely
randomized trees, the multilayer perceptron and least squares methods respectively.
We conclude the chapter by presenting two popular benchmark domains, other than
the HIV domain, that we will be using for experimentation.
3.2 The reinforcement learning paradigm
The material in this section is based on Chapters 2 and 3 of Sutton & Barto (1998).
Reinforcement learning (RL) is a machine learning paradigm in which a decision
maker or agent interacts with an environment to learn a particular task. Typically,
agent-environment interaction involves three signals: a state signal describing the cur-
rent situation of the environment, an action signal that allows the agent to influence
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the environment, and a reward signal produced by the environment to provide the
agent with feedback on its immediate performance or to evaluate the quality of taking
a particular action at a certain time (Bus¸oniu et al., 2010). The aim of the agent is
to make decisions optimally by determining those actions that maximize accumulated
future rewards.
Agent-environment interaction may be broken down over a sequence of discrete time
steps, t = 0, 1, 2, . . .. At each of these points in time, the agent receives a summary of
the conditions of the environment in the form of its state at time t, st. Here st ∈ S where
S is the collection of all possible states. Based on the environment’s situation, the agent
selects an action at time t, at ∈ A, where A is the set of all available actions. Applying
a particular action causes the environment to transition to a new state st+1. The agent
receives a scalar reward rt+1 ∈ R assessing the quality of the transition to the new state.
Negative rewards may be viewed as penalties for making a poor choice of action at a
particular time. Once the agent receives information about the new conditions of the
environment, the whole cycle of agent-environment interaction repeats.
The behaviour of an agent is governed by the sequence of actions it takes following
each state it finds itself in. This is known as the agent’s policy, pi : S → A. Alternatively,
in cases when policies are non-deterministic, the agent’s policy may also be viewed as
a mapping of states to probabilities of actions. The behaviour of the environment may
be described in terms of its dynamics which dictate how the state changes as a result
of the agent’s choice of actions. In a deterministic setting, taking a given action from a
given state always results in the same next state; in a stochastic setting, the next state
may vary (Bus¸oniu et al., 2010). Together, the states, actions, rewards and environment
dynamics constitute a Markov Decision Process.
3.2.1 Markov decision processes
The interaction between an agent and its environment can be modelled in terms of a
Markov Decision Process (MDP). Formally, an MDP is a tupleM = (S,A,P,R), where
S is the set of all possible environmental states and A is the set of actions the agent
can take. P is the set of transition probabilities defining the likelihood of ending up in
each possible next state, s′, having taken any action, a, from any state, s. R is the set
of numerical rewards received after each transition. Given a particular state, s, and an
action a, the probability of moving to a state, s′, is given by
P (s, a, s′) = P
[
st+1 = s
′|st = s; at = a
]
. (3.2.1)
Similarly, the expected reward for taking an action a from a state s and ending up in a
state s′ is given by,
R(s, a, s′) = E
[
rt+1|st = s; at = a; st+1 = s′
]
. (3.2.2)
Here, the set P consists of all transition probabilities P (s, a, s′) and the set R consists
of all numerical rewards R(s, a, s′).
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3.2.2 The return function
The agent’s goal is to maximize the accumulated future rewards. The return function, or
simply the return, Rt, is a long-term measure of rewards. We can distinguish between
finite-horizon and infinite-horizon models. In a finite-horizon model, the return is
calculated over a finite number of time steps. The following equation gives the return
over a finite-horizon:
Rt = rt+1 + rt+2 + . . .+ rt+K−1. (3.2.3)
Here, K is the number of steps before the terminal state.
In certain complex tasks where the sequence of actions taken by an agent is long
or infinite, immediate rewards may be valued more than those in the future. In these
cases, a discount factor γ ∈ (0, 1) is introduced. This discount factor is a measure of
how much foresight the agent has in considering its rewards (Bus¸oniu et al., 2010). The
return may then be expressed as
Rt =
∞∑
k=0
γkrt+k+1. (3.2.4)
Note that we need γ < 1 to ensure that the infinite sum converges. In what follows, we
shall use the infinite-horizon model for the return.
3.2.3 The value function
It is possible for some states of the environment to be more advantageous than others.
When following a policy pi, we can estimate how good it is to be in a certain state
in terms of a value function. That is, we can value a state under a particular policy
by the expectation of future reinforcement or rewards an agent receives. Using this
information, the value, V pi : S → R, of a given state s at an arbitrary time t, if an agent
follows a policy pi, is given by
V pi(s) = Epi
[
Rt
∣∣∣∣ st = s] = Epi
[ ∞∑
k=0
γkrt+k+1
∣∣∣∣ st = s
]
. (3.2.5)
Here, the operator Epi[·] represents the expected value given that the agent follows policy
pi.
A key property of the value function is that it satisfies a recursive relationship.
Formally, this relationship may be expressed according to the Bellman operator under
a policy pi, Bpi(·), as follows:
Bpi(V pi) = V pi. (3.2.6)
The existence of this recursive relationship means that we can rewrite the expectation
in Equation 3.2.5 as a summation over states and hence express the value of a particular
state in terms of the value of its successor states (Sutton & Barto, 1998)1:
V pi(s) =
∑
a∈A
pi(s, a)
∑
s′∈S
P (s, a, s′)
{
R(s, a, s′) + γV pi(s′)
}
. (3.2.7)
1The interested reader should refer to Sutton & Barto (1998) for this proof.
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Here pi(s, a) is the probability of taking an action a from the state s. Equation 3.2.7
is known as the Bellman equation for V pi. Intuitively, an agent can take a number of
actions from a given state s, each of which may result in different subsequent states s′ and
different rewards. Equation 3.2.7 averages the outcomes by weighting each according to
its probability of occurring.
We can also define the optimal value for a state, V ∗(s) in terms of the Bellman
optimality equation, i.e.
V ∗(s) = max
pi
V pi(s) = max
a∈A
∑
s′∈S
P (s, a, s′)
{
R(s, a, s′) + γV ∗(s′)
}
. (3.2.8)
Here, determining the optimal value involves selecting the policy and hence actions,
which maximize the value of a particular state.
The Bellman optimality equation is a central construct in RL algorithms. Given the
optimal value function for a particular RL problem, we can derive the optimal policy by
considering those actions that maximize the Bellman optimality equation. The optimal
policy for a particular RL problem is
pi∗(s) = arg max
a∈A
∑
s′∈S
P (s, a, s′)
{
R(s, a, s′) + γV ∗(s′)
}
, (3.2.9)
where arg maxa∈A finds the action which maximizes the expression.
It is not always possible to compute an optimal policy directly from the Bellman
optimality equation. In these cases, it is useful to estimate the value of a state-action
pair (s, a) in terms of a Q-function, Qpi : S × A 7→ R. Qpi(s, a) defines the expected
long-term return of applying action a when in state s under a policy pi. That is,
Qpi(s, a) = Epi
[
Rt
∣∣∣∣ st = s; at = a] = Epi
[ ∞∑
k=0
γkrt+k+1
∣∣∣∣ st = s; at = a
]
. (3.2.10)
Like the value function V pi, it is possible for us to express Qpi recursively and use this
recurrence relation to compute the exact Q-value for all state-action pairs (s, a). Here,
Qpi(s, a) =
∑
s′∈S
P (s, a, s′)
{
R(s, a, s′) + γ
∑
a′∈A
pi(s′, a′)Qpi(s′, a′)
}
, (3.2.11)
where pi(s′, a′) is the probability of taking action a′ from a state s′ under the policy pi.
For notational purposes, we can define R : S ×A → R as the expected reward for a
state-action pair (s, a) where,
R(s, a) =
∑
s′∈S
P (s, a, s′)R(s, a, s′). (3.2.12)
Then we can rewrite the Bellman equation for Qpi in matrix form as,
Qpi = R+ γPΠpiQ
pi, (3.2.13)
where P is a stochastic matrix of the transition probabilities of size |S||A| × |S| such
that P((s, a), s′) = P (s, a, s′), and Πpi is a stochastic matrix with dimensions of size
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|S| × |S||A| describing the policy pi. That is, we can choose to write the policy matrix
Πpi in the following form,
Πpi(s
′, (s′, a′)) = pi(s′, a′). (3.2.14)
In this case, the optimal value for a state action pair, Q∗(s, a) is
Q∗(s, a) = max
pi
Qpi(s, a) =
∑
s′∈S
P (s, a, s′)
{
R(s, a, s′) + γmax
a′∈A
Q∗(s′, a′)
}
. (3.2.15)
Here, the optimal policy can be written as
pi∗(s) = arg max
a∈A
∑
s′∈S
P (s, a, s′)
{
R(s, a, s′) + γmax
a′∈A
Q∗(s′, a′)
}
. (3.2.16)
RL algorithms can typically be classified into one of three categories, depending on the
strategy they employ to determine an optimal policy. These are: value iteration, policy
iteration and policy search (Bus¸oniu et al., 2010). Value iteration methods search for
the optimal value function by iteratively computing the maximal returns for each state
or state-action pair; the optimal policy is then derived from the optimal value func-
tion. Policy iteration methods determine an optimal policy by constructing a sequence
of monotonically improving policies and evaluating the performance of each of these
policies. Policy search algorithms use optimization methods to explicitly search for an
optimal policy. In this study, we will be focusing on value iteration methods and policy
iteration methods only.
3.3 Model-based value iteration
When a model of the MDP dynamics and reward function is available, it is possible for
the Bellman optimality equation to be solved directly. In this case, the optimal value
function may be computed iteratively and can be used to derive an optimal policy.
Model-based value iteration begins by arbitrarily assigning an estimate to either the Q-
function or V -function and progressively refining this value until no further refinement
is required. At each iteration, the relevant value function is updated by transforming
the original associated Bellman equation into an update rule. We present a Q-value
iteration algorithm here (Bus¸oniu et al., 2010). We use the notation Qk to denote the
value of the Q-function after k iterations of the learning algorithm, where k = 0, 1, 2, . . ..
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Algorithm 1 Pseudocode for the Q-value iteration algorithm (Bus¸oniu et al., 2010).
Input: Transition dynamics P , reward function R and discount factor γ .
Output: Optimal Q-function, Q∗.
Q iteration(P , R, γ):
Initialize Q arbitrarily everywhere on S × A. For example, Q0(s, a) ← 0 for each state-
action pair (s, a)
k = 0
repeat
for each state-action pair (s, a) do
Qk+1(s, a)←
∑
s′ P (s, a, s
′) {R(s, a, s′) + γmaxa′∈AQk(s′, a′)}
end for
until Qk+1 = Qk
return Q∗ = Qk
3.4 Model-free value iteration: the Q-learning framework
In most situations, a complete model of the MDP dynamics will not be available. In
these cases, the agent is required to learn a task without prior knowledge of the en-
vironment’s transition function or the probability distribution of the random variables
concerned. The Q-learning framework due to Watkins (1989) is one of the most im-
portant and widely used model-free off-policy techniques developed in the context of
reinforcement learning, whereby an optimal policy can be learned while evaluating an-
other policy. Since Q-learning is an off-policy method, an optimal Q-function, Q∗, can
be approximated directly, independent of the policy being evaluated at a certain time
(Sutton & Barto, 1998). In particular, the algorithm operates by learning a Q-function
which gives us an estimate of the expected return given that a particular action is taken
from a certain state and the optimal policy is followed thereafter. Typically a tabular
representation of the Q-values for each (s,a) pair is maintained. Initially, these Q-values
are assigned arbitrary values which are then modified throughout the learning process.
During Q-learning an agent’s experience is divided into subsequences of repeated inter-
action called episodes. Learning progresses in a manner analogous to temporal difference
(TD)-learning (Sutton, 1988) where an agent takes an action at a certain state, eval-
uates its immediate reward and then updates its current estimate of the value of the
state based on the value of the resulting state (Watkins & Dayan, 1992). That is, the
value of a (s,a) pair is updated using the immediate reward that an agent receives with
the discounted estimated optimal future value. An episode reaches completion once the
resulting state st+1 is an absorbing or terminal state.
In its simplest form, the Q-learning algorithm makes use of a standard value iteration
type update where a previous value is modified on the basis of newly available data.
The Q-learning update rule is given by
Q(st, at)← (1− α)Q(st, at) + α
[
rt + γmax
at+1
Q(st+1, at+1)
]
. (3.4.1)
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Here rt represents the reward at time t, γ is the discount factor and α ∈ (0, 1] is the learn-
ing rate which measures the rate at which new information influences previously learned
values. The (1 − α) weight can be viewed as an inverse learning rate that is attached
to the old estimate of the value of the state-action pair (st, at). maxat+1 Q(st+1, at+1) is
an estimate of the optimal future value of the subsequent state st+1.
By rearranging terms, the Q-learning update rule 3.4.1 can be rewritten as follows:
Q(st, at)← Q(st, at) + α
[
rt + γmax
at+1
Q(st+1, at+1)−Q(st, at)
]
. (3.4.2)
We refer to Sutton & Barto (1998) for the Q-learning algorithm presented here as
Algorithm 2.
Algorithm 2 Pseudocode for the Q-learning algorithm (Sutton & Barto, 1998).
Input: Q(s, a) initialized arbitrarily; start state s0.
Output: Q(s, a) for all pairs (s, a)
Q learning(Q, s0):
repeat
Choose a for the current s on the basis of Q(s, a)
Take action a, observe reward r and resulting state s′
Q(s, a)← Q(s, a) + α {r + γmaxa′∈AQ(s′, a′)−Q(s, a)}
s← s′
until the end of the learning episode
return updated list of Q values
3.5 Batch reinforcement learning methods
Figure 3.1: Stages of batch reinforcement learning.
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Conventional reinforcement learning uses online learning to update policies. In this ap-
proach, the agent interacts with the environment dynamically and updates its control
policy at each time step (Sutton & Barto, 1998). However, in many medical domains
this may not be possible: the effects of having an untrained agent may be potentially
hazardous and impose an unacceptable risk to the patients concerned. In these situa-
tions, the agent and system cannot interact directly during learning, hence interaction
must be decoupled from the learning step (Lange et al., 2012). That is, experience from
agent-environment interaction must be collected beforehand through a series of experi-
mental trials. The agent is then trained on this set of previously recorded information
containing state, action and reward data. The policy that is learned from the samples
collected can be applied back to the environment for further sample collection and policy
refinement. Learning techniques that make use of pre-recorded data are termed batch
reinforcement learning or simply batch learning methods. Figure 3.1 shows the main
steps involved in the batch reinforcement learning problem.
As with the standard reinforcement learning problem, the aim of batch reinforcement
learning is to determine a policy such that the expected cumulative reward is maximized.
In general, the agent cannot make any assumptions about the manner in which transition
data is collected, since sampling may be completely random or in accordance to an
arbitrary policy (Lange et al., 2012). Popular examples of batch reinforcement learning
methods are the fitted Q-iteration algorithm due to Ernst et al. (2005) and the least
squares policy iteration method due to Lagoudakis & Parr (2003). We examine each of
these learning techniques at length in the rest of this chapter.
3.6 Fitted Q-iteration
The fitted Q-iteration (FQI) algorithm is a batch reinforcement learning technique in-
spired by the online Q-learning framework where an agent learns a Q-function without
explicit knowledge of the transition probability function. Unlike the Q-learning algo-
rithm, the exact Q-function representation is replaced by an approximation, and a set
of predetermined four-tuples, F = {(sit, ait, rit, sit+1)}i=1,...,|F|, is used. Here, |F| is the
cardinality of the set F and each tuple is an example of the one-step transition dynamics
of the system.
Typically, in domains with small or finite state and action spaces, it is possible for
the Q-function to be represented as a table where one entry exists for each state-action
pair. Deriving an optimal policy for the Q-function in this case, is straightforward.
However for larger problems where state or action spaces are continuous, this is not
feasible since an infinite number of states or actions may exist. In these instances,
the Q-value function must be approximated to generalize similar circumstances and/or
actions. Furthermore, in situations where batch reinforcement learning methods such
as fitted Q-iteration are used, an approximation of the Q-function must be derived
using sparse sets of four-tuples (Ernst et al., 2005). This problem is common in large
reinforcement learning systems and is referred to as the generalization problem (Sutton
& Barto, 1998).
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To overcome the generalization problem, function approximation techniques are
used. Function approximators attempt to use examples from the Q-value function to
generalize the Q-values over a larger subset (Sutton & Barto, 1998). When attempt-
ing to estimate a value function, examples of available Q-values are used to construct
an approximation of the entire Q-function. Currently, a number of supervised learn-
ing techniques have been used as function approximators. In particular, Ormoneit &
Sen (1999) apply the idea of kernels to the fitted value iteration method due to Gordon
(1999). Here, the problem of approximating a Q-function is reformulated into a sequence
of kernel regression problems. Kernels are a non-parametric function approximator that
map two elements from a space of input patterns to a real number. This number may be
viewed as a similarity measure between the patterns on the input space (Bethke et al.,
2008). A formal definition of the kernel is provided below (refer to Bus¸oniu et al. (2010)
and Taylor & Parr (2009)) for details).
Definition 3.6.1. A kernel κ(·, ·) is a map that is defined over two state-action pairs
where κ : S ×A× S ×A → R. A symmetric kernel matrix, K, stores the kernel values
for all input pairs in a dataset. If K is a positive semi-definite matrix2, the kernel
function may be viewed as the inner product between two points (i.e. two state-action
pairs) in a higher dimensional space.
As with other non-parametric approximators, kernels are highly flexible since their
shape is dependent on the data used when running the associated reinforcement learning
algorithm (Bus¸oniu et al., 2010). By expressing the Q-function in terms of a series of
regression problems, Ormoneit & Sen (1999) allow for various regression algorithms to
be applied to the same problem.
The fitted Q-iteration algorithm builds on the idea of fitted value iteration pre-
sented in Ormoneit & Sen (1999). In particular, it constructs an approximation of the
Q-function iteratively. That is, on the first iteration, the algorithm produces an approx-
imation of the Q1-function, Q̂1, which corresponds to a one-step optimization (Ernst
et al., 2005). This approximation is produced by applying a regression algorithm to
training data where the input consists of the pairs (st, at) and the target output, y,
consists of the rewards rt (Ernst et al., 2005). Similarly, the N
th iteration produces an
approximation of the QN -function, Q̂N , which corresponds to an N -step optimization.
This approximation is calculated in the same manner as before except the target out-
put values are obtained from applying a value-iteration based update to the Q-function
approximation from the previous time-step. That is, the output values, y, are updated
using,
y = rt + γmax
a∈A
Q̂N−1(st+1, a). (3.6.1)
We note that any regression algorithm may be used to determine the mapping Q :
S × A → R. Examples of techniques employed to learn this mapping include using
extremely randomized trees (Geurts et al., 2006), neural networks (Riedmiller, 2005a),
sparse Gaussian processes (Rasmussen & Williams, 2006) and kernel-based methods
2We refer the reader to Hoffman et al. (2008) for a description of this mathematical property.
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(Ormoneit & Sen, 1999). For the purposes of this research, we focus on extremely
randomized trees and neural networks only. Reasons for this are based on results from
Ernst et al. (2005) where the advantages of extremely randomized trees are highlighted in
comparison to classical approaches such as tree-bagging, pruned CART trees, KD-trees,
and other supervised learning techniques such as k-nearest neighbours. In particular,
Ernst et al. (2005) demonstrate that ensembles of extremely randomized trees perform
significantly better when dealing with large state spaces. Reasons for using neural
networks as opposed to other supervised learning techniques are based on the popularity
of the technique. Fitted Q-iteration has often been used with neural networks in the
past and these results are well-documented and frequently cited.3
As N → ∞, the approximation, Q̂N , is refined and converges to the actual Q-
function. The interested reader should refer to Ernst et al. (2005) for the proof of
convergence of the fitted Q algorithm.
3.6.1 The algorithm
We refer to Ernst et al. (2005) for the following fitted Q-iteration algorithm.
Algorithm 3 Pseudocode for the fitted Q-iteration algorithm (Ernst et al., 2005).
Input: A set F = {(sit, ait, rit, sit+1)|i = 1, . . . , |F|} of four-tuples, discount factor γ,
maximum number of iterations Nmax and a regression algorithm.
Output: Q̂∗ = Q̂N .
Fitted Q-iteration(F , γ, Nmax):
Initialize number of iterations N to 0
Initialize Q̂N everywhere on S ×A
repeat
N ← N + 1
Build a training set T S from F where T S = {(xi, yi), i = 1, 2, . . . , |F|} based on
Q̂N−1 and on the set of four-tuples F . Here (xi, yi) are given by
xi = (sit, a
i
t) (3.6.2)
yi = rit + γmax
a∈A
Q̂N−1(sit+1, a). (3.6.3)
Deduce the value Q̂N (s, a) using non-parametric regression on (x
i, yi).
until Q̂N is satisfactory or Nmax has been reached.
return updated Q̂N values
The algorithm builds a training set T S using a set of one-step transitions and calculates
a new target Q-value with each transition. A supervised learning technique is used to
train a function approximator on the training set. The resulting approximation Q̂N
is an approximation of the Q-function after N -steps of value iteration performed on
the state-action value function (Lange et al., 2012). Consecutive runs of the regression
3See for instance Riedmiller (2005a).
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algorithm are entirely independent (Ernst et al., 2005). The implications of this are
that it is possible to adapt the model learned at each step so as to find a Q-function
that best models the input data.
The learning process continues until a certain predefined number of iterations, Nmax
has been reached or the difference between the Q-functions from successive iterations
is significantly small i.e. the Q-function has converged reasonably. Once an accurate
enough representation of the actual Q-function has been obtained after N steps where
N is arbitrarily large, an optimal stationary control policy, pi∗N , can be determined using
pi∗N (s) = arg max
a∈A
Q̂N (s, a). (3.6.4)
The existence of such a policy is a classical result from dynamic programming theory
(see for instance Bellman (1957)).
3.7 Extremely randomized trees
Typically when dealing with continuous state spaces consisting of numerous features that
interact in a complex way, determining a suitable representation for the Q-function is
difficult. In such situations, it may be necessary to use non-linear regression techniques
to subdivide the space into smaller regions to which we can apply simple models and
derive an approximation. Each subregion is partitioned into successively smaller regions
until an acceptable level of interaction between features is observed. This procedure
is referred to as recursive partitioning. Recursive partitions may be represented as
regression trees where each leaf node represents a cell of the overall partition with a
particular model or label associated with it; the branches represent the combining of
features that ultimately result in these labels (Strobl et al., 2009).
3.7.1 Single tree regression
Single tree regression grows one regression tree from a training set and uses it for the
classic purposes of prediction and classification. Trees are grown by splitting a sample
set into smaller subsets on the basis of certain attributes. Splitting occurs in accordance
with certain criteria: most often, the split which optimizes the associated node’s entropy
is chosen. Informally, entropy is a measure of disorderedness or information content of a
set. When we split a set of samples into two smaller subsets on the basis of a particular
attribute, we choose the attribute which maximizes the difference between these two
sets. That is, we select the split that reduces the disorderedness the most or maximizes
the information gained from performing the split. Popular regression techniques that
produce a single tree are CART, KD-tree, ID3, C4.5 and QUEST (Marsland, 2009).
These trees are often pruned to improve their prediction accuracy (Ernst et al., 2005).
3.7.2 Ensembles of extremely randomized trees
Extremely randomized trees, also called extra trees, refer to a class of unpruned regression
trees used for the purposes of prediction and classification. As with standard regression
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trees, extra trees approximate the relationship between an input x and output y using
a set of samples. They do so by employing a top-down approach to growing trees: the
input space is divided into several partitions that are refined progressively to produce
a reasonable approximation. Specifically, within the context of fitted Q-iteration, extra
trees can be used to partition the input space of a set of samples to produce a suitable
Q-function approximation (Wehenkel et al., 2006). Extremely randomized trees may be
viewed as an ensemble tree-based method for regression since sets of trees are grown
to derive an approximation. In particular, the extra trees algorithm constructs a forest
of regression trees at each iteration and averages the outputs of each tree to produce
a prediction. It is thought that the predictions of multiple classifiers can be used to
produce a single classifier that exhibits improved prediction accuracy in general (Geurts
et al., 2006). Unlike classical tree-based ensemble methods, extra trees are constructed
by selecting cut points at random. That is, each tree grows by choosing k random split
points at each node. This, in turn, requires k random candidate attributes or input
variables comprising the state and/or action space to be selected, and determining a
random split on each of these attributes (Geurts et al., 2006). The best split which
maximizes a certain score measure is retained (Wehenkel et al., 2006). Trees are grown
recursively until the outputs are constant or contain less than a specified number of
samples, nmin. Furthermore, the entire training sample is used to grow trees at each
iteration as opposed to the bootstrapping techniques employed by similar methods such
as tree-bagging (Geurts et al., 2006). We discuss the details of the extra trees algorithm
in the next section.
3.7.3 The extra trees algorithm
The complete extra trees algorithm is presented in Algorithm 4 (Geurts et al., 2006).
The algorithm uses three parameters, nmin, k and M to build an ensemble model of
extra trees recursively from a given training set, T S. nmin is the smallest sample size
required to split a node of a tree in the ensemble; k is the number of attributes selected
at each node of a tree that are used to determine a split point; M is the number of
trees in the ensemble (Geurts et al., 2006). To construct an individual tree, a root
node is initially created containing the entire training set of samples. The root node is
subsequently split to produce left and right child nodes respectively. Splitting involves
selecting an attribute or direction to split on, a, as well as a corresponding scalar cut
value, ac. Once a node is split, the set of samples associated with the node is divided
into two disjoint sets, T S l and T Sr, containing the samples to the left and right of the
split-point respectively. Using set theoretic notation, we can denote the sets T S l and
T Sr as,
T S l = {(xi, yi) ∈ T S|xia < ac}, (3.7.1)
T Sr = {(xi, yi) ∈ T S|xia ≥ ac}. (3.7.2)
Here (xi, yi) is the ith input-output pair of the initial training set where i = 1, 2, . . . , |F|,
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Algorithm 4 Pseudocode of the extra trees algorithm (Geurts et al., 2006).
Pick a random split(T S, a):
Input: A training set T S and an attribute to split on a.
Output: A split [a < ac].
Determine the maximal and minimal values, aT Smax and aT Smin, of the attribute a in T S
Select a splitting point ac uniformly from [a
T S
min, a
T S
max]
return the split [a < ac]
Build an extra tree(T S, nmin, k):
Input: A training set T S, parameters nmin, k.
Output: A tree T .
return a leaf node whose value is given by the average output in T S if
(i) |T S| < nmin, or
(ii) the output is constant in T S, or
(iii) the candidate attributes are constant in T S
else
Choose k non-constant attributes {a1, a2, . . . , ak} at random in T S
Create k random splits {ac1 , ac2 , . . . , ack} where aci = Pick a random split(T S, ai),
∀i = 1, 2, . . . , k
Pick an attribute a and split ac such that Score(a, ac, T S) = maxi=1,2,...,k Score(ai, aci ,
T S)
Split T S into two subsets, T S l and T Sr, according to a and ac.
Build trees Tl = Build an extra tree(T S l, nmin, k) and Tr =
Build an extra tree(T Sr, nmin, k) using the subsets T S l and T Sr
Build a node with split ac with T S l and T Sr as left and right subtrees of the node
return the resulting tree T .
Build an extra tree ensemble(T S, M , nmin, k):
Input: A training set T S, parameters M , nmin, k.
Output: An ensemble of trees E .
for j = 1 to M do
Tree Tj = Build an extra tree(T S, nmin, k)
Add Tj to ensemble E
end for
return E = {T1, T2, . . . , TM}
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xia is the i
th input value at the attribute a and ac is the split value (Bus¸oniu et al., 2010).
The splitting process continues at each child node produced thereafter. Each leaf node
containing more than nmin samples, where nmin ≥ 2, is split.
To determine precisely how a node is split, k non-constant attributes, ai, with k
corresponding cut-points, aci , where i = 1, 2, . . . k, are selected. These cut-points are
drawn uniformly in the range of their associated attribute. That is, for an attribute,
ai, we randomly choose the cut point, aci , such that aci ∈ [aimin , aimax ], where aimin
and aimax represent the minimal and maximal values of the attribute ai respectively,
∀i = 1, 2, . . . k. Ultimately the cut point, ac, corresponding to the attribute, a, that
maximizes the score
Score(a, ac, T S) =
Var[y|T S]− |T Sl||T S| Var[y|T S l]− |T Sr||T S| Var[y|T Sr]
Var[y|T S] , (3.7.3)
is retained. Here, Score(a, ac, T S) denotes the score of splitting the training set T S
on the attribute a according to the split value ac, and Var[·] is the variance of the
output y in the associated training set (Geurts et al., 2006). The score may be viewed
as a variance reduction over time on the output of the original training set based on
the Shannon entropy: we continue to split nodes of the tree until the output observed
remains constant or until the variance of the output is reduced sufficiently. To perform
a single split, we evaluate each of the k randomly selected cut points according to the
information gained and choose to split the attribute which maximizes this information
gain. In doing so, we can determine which attributes are most relevant: attributes with
a higher mutual information tend to be tested first and are hence used for splitting
earlier than others. Intuitively, we aim to select those attributes that split the data
in such a way that the samples of each successor node belong to a single class or are
as “pure” as possible. When this occurs, the splitting procedure reaches completion
since no new information can be gained from further splitting. We refer the reader
to Wehenkel (1996) for a detailed treatment of uncertainty measures such as Shannon
entropy, that are used for decision tree construction.
The parameters k, nmin and M serve different purposes: M dictates the degree of
variance reduction when aggregating the results from the ensemble of trees while nmin
determines the influence of averaging output noise and influences the size of the trees
produced. Larger nmin values produce smaller trees with less variance (Wehenkel et al.,
2006). The parameter k determines how attributes are selected (Geurts et al., 2006).
In particular, it is a direct measure of the randomization strength of the attribute se-
lection process: a lower k results in trees with stronger randomization; for the specific
case of when k = 1, the resulting splits are entirely independent of the output values
of the training samples (Geurts et al., 2006). This results in the production of totally
randomized trees which are a special instance of extra trees. The values of the param-
eters k, nmin and M should be adjusted according to the problem at hand. However,
larger k-values are suited to problems with a large number of input variables, few of
which are pertinent; larger nmin values are used in domains where the output variable
is particularly noisy (Wehenkel et al., 2006).
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Once a tree is constructed, determining its output is relatively straightforward: start-
ing at the root node, a test consisting of the node’s split value and cut-point are applied
to the node. The result of this test determines which subtree to traverse. This continues
until a leaf node is reached. The value of the leaf is returned as the average output of
the samples associated with it. This procedure is outlined by Algorithm 5 (Bus¸oniu
et al., 2010).
It is possible to express the structure of the extra trees approximator in terms of
kernels. If we consider the jth regression tree, Tj , in the ensemble of trees E , we can
define a function pj(x) that assigns each input x to the region or partition it belongs to
given by the tree Tj . Assume the prediction or approximate output of the j
th regression
tree in an ensemble is given by ŷj(x). The prediction may be viewed as the average
output of the samples belonging to the region pj(x). Using kernels, this can be written
as:
ŷj(x) =
|F|∑
i=1
κ(x, xi)yi. (3.7.4)
The kernel κ(x, xi) is given by
κ(x, xi) =
1{xi ∈ pj(x)}∑|F|
i′=1 1{xi′ ∈ pj(x)}
, (3.7.5)
where 1{·} denotes the indicator function that produces 0 if its argument is false and 1
if it is true (Bus¸oniu et al., 2010).
Using Equation 3.7.4, we can express the final prediction or output produced by the
ensemble of regression trees as an average of the predictions of each tree. That is,
ŷ(x) =
1
M
M∑
j=1
ŷj(x). (3.7.6)
The final output can also be expressed in terms of kernels where the kernel function
κ(x, xi) is given by
κ(x, xi) =
1
M
M∑
j=1
1{xi ∈ pj(x)}∑|F|
i′=1 1{xi′ ∈ pj(x)}
. (3.7.7)
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Algorithm 5 Pseudocode of the algorithm used to predict the output of a tree (Bus¸oniu
et al., 2010).
Input: A tree T and a point x.
Output: The output of the tree T .
while T is not a leaf
(a, ac) ← test corresponding to root node of T .
if xa < ac then
T ← Tl
else T ← Tr
end if
end while
Return the output of T
3.8 Neural fitted Q-iteration
Figure 3.2: Multilayer perceptron structure for neural fitted Q-iteration (Figure adapted
from Riedmiller (2010)).
Neural fitted Q-iteration (NFQ) is a batch reinforcement learning technique based on the
fitted value iteration algorithm due to Ormoneit & Sen (1999). Like other batch learning
techniques, neural fitted Q-iteration is based on the principle of storing and reusing
transition experiences; in particular, this method may be viewed as a modified version
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of the experience-replay technique since value iteration is executed on all the transition
samples collected at a time (Riedmiller, 2005b). In Section 3.7, we introduced the idea of
fitting training data to a value function using ensembles of regression trees. Neural fitted
Q-iteration attempts to solve the same approximation problem using the multilayer
perceptron as opposed to regression trees to perform non-parametric regression on a
set of input-output pairs. A multilayer perceptron (MLP) is a feedforward artificial
neural network with one or more hidden layers that maps a set of input data to a set
of corresponding outputs. Here, the aim of an MLP is to learn an optimal Q-function
successfully from a relatively sparse set of samples without requiring explicit knowledge
of the system’s dynamics (Riedmiller, 2005a). That is, the neural fitted Q-iteration
algorithm attempts to provide a model-free data-efficient alternative to approximating
the Q-function. The optimal Q-function can in turn be used to derive an optimal policy
for the domain of interest.
Although Riedmiller (2005a) demonstrates that neural networks may be applied di-
rectly to the online Q-learning problem by introducing an error measure that can be
minimized using gradient descent techniques, this procedure is slow and is not suited to
domains where the agent and system cannot interact directly during learning. Instead,
the neural fitted Q-iteration algorithm uses a set of transition experiences F collected
through prior agent-environment interaction. The Q-function update is then performed
offline on the basis of these transitions. Riedmiller (2005b) observes that the use of
previously collected transition samples enables advanced supervised learning techniques
to be used to derive an approximate Q-function; this ultimately leads to faster con-
vergence than applying standard gradient-descent techniques to the online Q-learning
framework.
3.8.1 The multilayer perceptron as a function approximator
In order to model a set of observational data and determine an adequate approximation
of the value function, non-linear regression models need to be used. Non-linear regression
is a form of regression analysis in which a set of training data is modelled as a non-linear
combination of input variables and parameters. The basic idea is to adequately express
the relationship between a set of input and output values.
The multilayer perceptron (MLP) is a feedforward neural network which can serve as
a value function approximator within the context of RL. Typically, an MLP consists of
multiple layers that direct information flow (Marsland, 2009). The first layer is termed
the input layer ; the last is termed the output layer ; layers between the input and output
layers are termed hidden layers. Each layer is comprised of a pre-specified number of
nodes that are connected by a set of weighted edges to form a weighted directed graph.
The input nodes are responsible for distributing signals to the nodes of the first hidden
layer. Each node at a particular hidden layer is responsible for transforming the signal
from the previous layer to an output signal that can be distributed across the next
layer. Changing a signal from one hidden layer to the next involves using an activation
function. That is, the output from a hidden node is calculated as a weighted sum of the
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signals from the previous layer that is transformed using an activation function. Exam-
ples of activation functions include the sigmoid function, the Heaviside step function and
the Gaussian function (Marsland, 2009). Training a neural network involves comparing
the output values and targets for a given set of inputs to determine an error value; this
error can be used to determine how to update the weights of the directed edges within
the MLP. A variety of training algorithms exist, most of which apply some modified
form of gradient-descent to determine the weights of the edges within the network; pop-
ular examples include the backpropagation algorithm and the resilient backpropagation
algorithm. The interested reader should refer to Rumelhart et al. (1986) and Riedmiller
(1994) or Riedmiller & Braun (1993) respectively, for detailed descriptions of each of
these training techniques.
Within the RL framework, it is possible to use the multilayer perceptron to represent
a Q-function. Here, a simple backpropagation neural network would suffice with one
input node corresponding to each dimension of the state space and action space and one
output node corresponding to the approximate Q-value. The number of hidden layers
and nodes would depend on the problem being solved. Using MLPs in this context
offers certain advantages over other function approximation techniques: in particular,
the MLP makes no assumptions about how the data is distributed. As a result, the
MLP can be used to model highly non-linear functions and is capable of adapting to
new circumstances or suitably generalizing unseen data. Figure 3.2 has been adapted
from Riedmiller (2010) and shows the structure of an MLP when applied to the neural
fitted Q-iteration algorithm. In particular, the set of inputs used by the neural network
consists of the state-action pairs made available from the sample set; the output consists
of the corresponding Q-values.
3.8.2 The algorithm
The neural fitted Q-iteration procedure is given by Algorithm 6. We observe that the
algorithm largely follows the fitted Q-iteration algorithm presented in Section 3.6. Here
the non-parametric regression step is realized by the multilayer perceptron (Riedmiller,
2005a). In particular, the multilayer perceptron is trained on the set of input-output
pairs, (x, y), consisting of state and action information for the transition, and our current
estimate of the Q-function respectively. The structure of the multilayer perceptron used
is largely dependent on the problem at hand; training from the set of patterns occurs
repeatedly for a specified number of epochs or until the training pattern is learned
(Riedmiller, 2005b). We use the notation B to represent any MLP training algorithm
of the user’s choice.
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Algorithm 6 Pseudocode of the neural fitted Q-iteration algorithm (Riedmiller, 2005a).
Input: A set F = {(sit, ait, rit, sit+1)|i = 1, . . . , |F|} of four-tuples, discount factor γ, max-
imum number of iterations Nmax and an algorithm B to train the multilayer perceptron.
Output: Q̂∗ = Q̂N .
Neural fitted Q-iteration(F , γ,Nmax):
Initialize number of iterations N to 0
Initialize Q̂N everywhere on S ×A (i.e. initialize multilayer perceptron.)
repeat
N ← N + 1
Build a training set T S from F where T S = {xi, yi), l = 1, 2, . . . , |F|} based on Q̂N−1
and on the set of four-tuples F . Here (xi, yi) are given by:
xi = (sit, a
i
t) (3.8.1)
yi = rit + γmax
a∈A
Q̂N−1(sit+1, a) (3.8.2)
Apply algorithm B to train neural network with the pattern set T S to deduce Q̂N (s, a)
until Q̂N is satisfactory or Nmax has been reached.
return updated Q̂N values
3.9 Least Squares methods for approximate policy evalu-
ation
An alternative to the class of approximate value iteration algorithms presented in the
previous sections is the class of approximate policy iteration methods. Traditional pol-
icy iteration methods work by iteratively evaluating and improving policies on the basis
of computing either the value function or state-action value function directly (Bus¸oniu
et al., 2012). Here, the state-action space is finite and hence exact representations of
the value function and the policy under consideration, are possible. The generalization
problem in most practical applications of reinforcement learning means that explicit
representation of the policy and value function is not feasible. In these cases, approxi-
mate policy iteration methods must be used. Usually this requires the Bellman equation
for the value function to be solved approximately.
Existing approximate policy iteration algorithms typically exploit the linearity of the
Bellman equation for a particular value function. By doing so, it is possible for the value
function to be represented using linear architectures. Consider the approximation for
the Q-value function under a linear approximation architecture: here, a single Q-value
for the state-action pair (s, a), may be expressed as a linear parametric combination of
k basis features or functions using,
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Q̂pi(s, a;w) =
k∑
j=1
φj(s, a)wj . (3.9.1)
Here, φj(s, a) are the basis functions of the state-action pairs and wj are the weights
associated with these functions, ∀j = 1, 2, . . . , k. The basis functions may be viewed as
arbitrary non-linear functions of state-action pairs that are used to capture the under-
lying structure of the Q-function in an attempt to reduce the dimensionality of large
state-action space to Rk where k ≤ |S||A| in general. Note that selection of appropriate
basis functions is critical for good performance of approximate policy iteration meth-
ods; these basis functions must be linearly independent to prevent redundant parameters
(Lagoudakis & Parr, 2003). Common choices for basis functions include Gaussian radial
basis functions and polynomial bases of varying degrees (Lagoudakis & Parr, 2003).
Assume Q̂pi is a vector of approximate state-action values determined using a linear
approximation with basis functions φj , ∀j = 1, 2, . . . , k and corresponding parameters
weighting the basis functions wj . We can define φ(s, a) to be column vector of length
k where the jth entry coincides with the basis function φj at the same state-action pair
(s, a). That is, φ(s, a) is given by
φ(s, a) =

φ1(s, a)
φ2(s, a)
. . .
φk(s, a)
 . (3.9.2)
We can then rewrite Q̂pi in vector form for all state-action pairs using,
Q̂pi = Φwpi, (3.9.3)
where wpi = (w1, w2, . . . , wk) is the set of weights for the set of basis functions under a
policy pi, and Φ is the matrix obtained by considering all the basis functions for every
state-action pair (s, a). That is,
Φ =

φ1(s1, a1) φ2(s1, a1) · · · φk(s1, a1)
φ1(s2, a2) φ2(s2, a2) · · · φk(s2, a2)
...
...
. . .
...
φ1(s|S|, a|A|) φ2(s|S|, a|A|) · · · φk(s|S|, a|A|)
 . (3.9.4)
In particular, the rows of the matrix Φ correspond all the basis functions used for rep-
resenting the value function for a particular state-action pair; the columns correspond
to the value of a particular basis function for all state-action pairs (Lagoudakis & Parr,
2003). The resulting system of equations of parameters 3.9.3 can then be solved using
least squares methods. We can distinguish between two classes of least squares methods
on the basis of their approach used to approximate a solution to the Bellman equation
for a value function. These are (i) projected policy evaluation and (ii) Bellman Resid-
ual Minimization (Bus¸oniu et al., 2012). Projected policy evaluation methods seek to
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determine an approximation for the value function by examining the projection of the
value function under the Bellman operator onto the space of representable value func-
tions (Bus¸oniu et al., 2012); Bellman Residual Minimization methods attempt to solve
the Bellman equation directly by calculating a Bellman residual (Bus¸oniu et al., 2012).
Informally, this residual can be seen as a minimization of the difference between the
approximation of a value function and its approximation under the Bellman operator.
Lagoudakis & Parr (2003) and Munos (2003) demonstrate at length that projected pol-
icy evaluation methods have certain advantages over Bellman Residual Minimization
methods and are hence a preferred method for approximating the value function. As a
result, we restrict our study to projected policy evaluation methods in this chapter.
3.10 Projected policy evaluation
We refer to Lagoudakis & Parr (2003) for the material in this section.
Recall the Bellman operator Bpi(·) that was introduced in Section 3.2.3 of this chap-
ter. A fundamental property of the value function Qpi that enables the existence of the
recursive Bellman Equation 3.2.11 is that it is a fixed point under the Bellman operator.
Formally, Qpi may be written as,
Bpi(Qpi) = Qpi. (3.10.1)
Hence if we are to determine a sufficient approximation for the value function, Q̂pi, the
approximation should be a fixed point under the Bellman operator and lie in the space
of representable Q-functions. That is,
Bpi(Q̂pi) ≈ Q̂pi. (3.10.2)
Intuitively, this means that for the approximation of the value function to be easily
representable, it must be forced to lie on the space spanned by the basis functions
Φ. This requires projecting the approximation of the value function onto the space
of representable value functions using the orthogonal projection (Φ(Φ>Φ)−1Φ>) that
minimizes the distance between the approximate value function and the projected ap-
proximation of the value function under the Bellman operator. That is, the projected
approximation of the value function under the Bellman operator should be as close to
approximate value-function as possible to prevent loss of information. By using Equa-
tion 3.2.13 and applying it to the approximate Q-function, this can be written in matrix
form as,
Q̂pi = Φ(Φ>Φ)−1Φ>(Bpi(Q̂pi)) = Φ(Φ>Φ)−1Φ>(R+ γPΠpiQ̂pi), (3.10.3)
Substituting Equation 3.9.3 for Q̂pi and rearranging the terms makes it possible for the
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solution of the system of equations to be represented as,
Φ(Φ>Φ)−1Φ>(R+ γPΠpiΦwpi) = Φwpi
⇒ Φ((Φ>Φ)−1Φ>(R+ γPΠpiΦwpi)− wpi) = 0
⇒ (Φ>Φ)−1Φ>(R+ γPΠpiΦwpi) = wpi
⇒ Φ>(R+ γPΠpiΦwpi) = Φ>Φwpi
⇒ Φ>(Φ− γPΠpiΦ)wpi = Φ>R. (3.10.4)
Hence we can deduce,
wpi =
(
Φ>(Φ− γPΠpiΦ)
)−1
Φ>R. (3.10.5)
It is possible to replace the standard orthogonal projection with a weighted projection
that determines how the error of the overall approximation is distributed. Assuming
ρ represents the matrix of the projection weights for each state-action pair, then the
solution to the system of equations can be rewritten as,
wpi =
(
Φ>ρ(Φ− γPΠpiΦ)
)−1
Φ>ρR. (3.10.6)
In this way, projecting the approximation of the value function leads to an easily rep-
resentable solution to the Bellman equation.
3.10.1 Least Squares Temporal Difference learning for Q-values
Recall the problem of determining a reasonable approximation Q̂pi for the state-action
value function under a particular policy using a set of previously collected samples.
The approximation may be expressed in terms of a linear architecture using k linearly
independent basis functions each weighted according to the weight vector wpi using
Equation 3.9.3. Least squares methods for approximate policy iteration typically make
use of parametric function approximators in the form of basis functions to determine
an optimal policy. Parametric approximators are mappings from a parameter space to
the space of functions that they attempt to represent (Bus¸oniu et al., 2010). The choice
of basis functions required is independent of the data for a particular problem and is
decided in advance. This means that determining a suitable approximation for the
state-action value function only requires us to learn the parameters wpi from Equation
3.9.3. In particular, the values of wpi may be deduced by solving the linear equations,
Awpi = b, (3.10.7)
where the matrices A and b can be calculated according to
A = Φ>ρ(Φ− γPΠpiΦ), (3.10.8)
b = Φ>ρR. (3.10.9)
In general, it is not possible for A and b to be computed directly since this requires ad-
vance knowledge of the transition probability function and reward structure. However,
3.10. PROJECTED POLICY EVALUATION 51
the values for A and b can be computed using a set of samples. This computation in
turn, makes it possible for the linear system 3.10.7 to be solved to produce a learned
estimate of parameters w˜pi and ultimately learn the value function.
By expanding A and b over the sum of all states s ∈ S and actions a ∈ A, Lagoudakis
& Parr (2003) demonstrate that A and b have special structures; given a set, F , of pre-
collected samples, it is possible to deduce learned estimates, A˜ and b˜, using,
A˜ =
1
|F|
|F|∑
i=1
φ(sit, a
i
t)
(
φ(sit, a
i
t)− γφ(sit+1, pi(sit+1))
)>
, (3.10.10)
b˜ =
1
|F|
|F|∑
i=1
φ(sit, a
i
t)r
i
t. (3.10.11)
For computational purposes the factor 1|F| may be dropped without changing the so-
lution of the system. Moreover, the system of equations 3.10.10 - 3.10.11 can easily
be transformed into update rules for A˜ and b˜ respectively. For a particular sample
(st, at, rt, st+1), these are,
A˜(t+1) = A˜(t) + φ(st, at) (φ(st, at)− γφ(st+1, pi(st+1)))> , (3.10.12)
b˜(t+1) = b˜(t) + φ(st, at)rt, (3.10.13)
where A˜(t) and b˜(t) are the current learned estimates for A and b under a certain policy
pi.
Using the incremental update rules 3.10.12 - 3.10.13, Lagoudakis & Parr (2003)
construct an algorithm that learns a value-function approximation. The Least Squares
Temporal Difference learning method for Q-values (LSTD-Q) learns an approximation
for the Q-function under a fixed policy pi using a batch of pre-recorded samples F . The
algorithm takes as input the set of samples used for learning, a discount factor γ, the
initial policy to be evaluated pi and the set of basis functions φ used to approximate
the state-action values. In return, it produces a vector of weights w˜ corresponding to
each basis function. This set of weights, when multiplied by the set of basis functions
can be used to determine Q̂. Selecting the action that maximizes the value Q̂ results
in an improved policy. When pi(st+1) is available for each resulting state st+1 in the
sample set, the approximate value function can be determined simply by determining
which basis function φ(st+1, pi(st+1)) to add to the matrix A˜. The implications of this
for sample-efficiency are tremendous: we can compute the approximate value function
for all policies considered in a single iteration of the algorithm using only one sample
set. Like the fitted Q-iteration method presented in Section 3.6, LSTD-Q makes no
assumptions about the way in which these samples are collected from an actual process.
The complete LSTD-Q algorithm is given by Algorithm 7. The key step of the algo-
rithm consists of updating the matrix A˜ upon encountering a new sample (st, at, rt, st+1).
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Algorithm 7 Pseudocode of the LSTD-Q algorithm (Lagoudakis & Parr, 2003).
Input: A set F = {(sit, ait, rit, sit+1)|i = 1, . . . , |F|} of four-tuples, discount factor γ,
policy pi, number of basis functions k, and basis functions φ.
Output: Vector of weight parameters w˜.
LSTD Q(F , γ, pi, k, φ):
Initialize A˜ to the k × k matrix of zeros.
Initialize b˜ to a k × 1 column vector of zeros.
for i = 1 to |F| do
A˜← A˜ + φ(sit, ait)
(
φ(sit, a
i
t)− γφ(sit+1, pi(sit+1))
)>
b˜← b˜+ φ(sit, ait)rit
end for
w˜pi ← A˜−1b˜
return w˜pi
3.10.2 Least Squares Policy Iteration
The Least Squares Policy Iteration (LSPI) technique makes use of LSTD-Q to determine
an improved policy. The algorithm takes as input a set of samples F , a discount factor
γ, a set of basis functions φ and some initial policy to evaluate pi0. Repeated calls are
made to the LSTD-Q method discussed in the previous section using the chosen set of
basis functions and the policy under consideration. This produces an improved weight
vector for the selected basis functions at each iteration. The process continues until
the difference between the weight vectors produced by successive calls to the LSTD-Q
method is significantly small; this is representative of the fact that the policy can no
longer be adequately improved. The final policy is returned in the form of a weight
vector which, using the basis functions, can be used to produce an approximation of the
value function.
The LSPI algorithm is given by Algorithm 8. The major steps involved in policy
iteration namely, policy evaluation and improvement, are shown.
Algorithm 8 Pseudocode of the LSPI algorithm (Lagoudakis & Parr, 2003).
Input: A set F = {(sit, ait, rit, sit+1)|i = 1, . . . , |F|} of four-tuples, discount factor γ, initial
policy pi0, number of basis functions k and basis functions φ.
Output: Policy pi.
LSPI(F , γ, pi0, k, φ):
Initialize policy pi′ to initial policy pi0
repeat
pi ← pi′
pi′ ← LSTD Q(F , γ, pi, k, φ)
until pi ≈ pi′
return pi.
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3.11 Benchmark domains
This section describes the benchmarks that are used for testing and comparing algorith-
mic performance in Chapter 5. Although the purpose of this research is to apply batch
reinforcement learning techniques specifically to the problem of HIV drug scheduling,
testing on benchmark domains can give us some indication of whether the implemen-
tations of the algorithms are working correctly in domains exhibiting similar properties
where larger data sets are available.
3.11.1 The swing-up acrobot
The swing-up acrobot is a two-link underactuated robot arm analogous to a double-
inverted pendulum or acrobat swinging on a bar. Like other underactuated systems,
the acrobot has fewer control inputs or actuators than degrees of freedom (Spong, 1998).
The first joint corresponding to the shoulder of the acrobot has no actuator; the second
joint at the elbow has an actuator and hence exerts a torque (Spong, 1995). The
acrobot’s state can be described in terms of four continuous state variables: two joint
positions, θ1 and θ2, and two corresponding joint velocities, θ˙1 and θ˙2 (Sutton & Barto,
1998). The aim of the agent is to swing the tip of the pendulum above the first joint
by an amount equal to the length of one of the links as quickly as possible (Sutton &
Barto, 1998). The actions of the agent can be described in terms of the torque. The
torque, τ , applied to the second joint can either have a fixed positive magnitude (a =
1), a fixed negative magnitude (a = -1) or no magnitude at all (a = 0). A reward of
-1 is given for every time step, t = 0.05, until the goal state is reached. The swing-up
acrobot control problem is illustrated in Figure 3.3 (Boone, 1997). The reader should
refer to Appendix A.1 for the system dynamics of the swing-up acrobot.
Figure 3.3: The swing-up acrobot (Boone, 1997).
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3.11.2 The mountain car
Figure 3.4: Illustration of the mountain car problem (Figure modified from Tanner
(2009)).
The mountain car task is a two-dimensional task where an underpowered car must
accelerate to the top of one side of a valley in a minimum amount of time. In many
cases, the acceleration of the car alone is not enough to move the car directly to the top
of the hill so the car has to move in the opposite direction first to gain enough potential
energy. Figure 3.4 illustrates the mountain car task (Tanner, 2009).
Within the reinforcement learning context, the car can be modelled as a point trav-
elling on a hill whose state can be expressed as a two-tuple (pt, vt) containing the car’s
position, pt, and its speed, vt, at some time t. At each time step, t = 0.1, the agent is
given a choice of 2 possible actions namely full throttle (at = 4) or reverse full throttle
(at = -4) (Sutton & Barto, 1998). That is, actions are restricted to the values {−4, 4}.
The initial velocity of the car is set to 0 while its position is fixed to -0.5. During
the course of learning, the velocity of the car is drawn from the interval [-3, 3]. The
agent’s goal is to reach the position 1 at the top of the valley. The reader should refer
to Appendix A.2 for the system dynamics of the mountain car task.
3.12 Conclusion
In short, this chapter has among other things, (i) introduced the reinforcement learning
paradigm using MDPs, (ii) discussed the need for batch reinforcement learning for
certain domains, (iii) presented the fitted Q-iteration algorithm (within the class of
value iteration methods) using both extremely randomized trees and neural networks
as function approximators, and (iv) presented the least squares policy iteration method
for batch learning based on policy iteration. The algorithms discussed in this chapter
are the core of our research and have been implemented for learning within the HIV
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domain. The next chapter examines exactly how the HIV drug scheduling task has been
formulated as an MDP and how the techniques presented here have been applied to this
problem.
Chapter 4
Research Methodology
4.1 Introduction
In this chapter, we present the methodology that was used to conduct this research. In
particular, the research problem described in Chapter 1 will be formalized in Section
4.2. Using the material provided from Chapters 2 and 3 as a basis along with the
problem definition, we formulate a series of specific research questions in Section 4.3.
Thereafter, we provide an outline of the methodology that has been used to answer these
questions. Specifically, we discuss the data that is used to test the performance of our
implementation in Section 4.5. This data is of two forms: the first is a set of simulated
data of a large scale that is used to compare relative performances of the algorithms and
test whether the outcomes of the learning techniques can potentially improve patient
wellness. The second is a set of real data that has been used to determine whether
RL techniques can provide suitable drug scheduling strategies for existing patients and
whether these strategies are consistent with those currently in place. Section 4.6 gives
a detailed description of how the HIV drug scheduling problem may be formulated as
an MDP; we examine MDP construction for both real and simulated data sets. We
conclude the chapter in Section 4.7 where we provide a summary of how each batch RL
technique was implemented to give the results presented in Chapter 5.
4.2 Aim of this research
Current HIV treatment regimens are focused at reducing pill burden for patients in an
attempt to reduce side-effects and improve overall patient adherence to drug therapy.
Typically, HIV drug therapy involves use of multiple drugs for treatment in order to pre-
vent the development of drug-resistant HIV strains. For these purposes, suitable drug
combinations need to be determined. Traditionally, this would involve conducting nu-
merous lengthy and expensive clinical trials. We propose modeling this drug-scheduling
problem as an MDP and using RL techniques to determine effective drug combinations.
The use of such techniques could be coupled with clinical trial investigations in the
future.
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4.3 Research questions
We can delineate the scope of this research by formulating the following research ques-
tions:
1. Is it possible to model the HIV drug scheduling problem as an MDP? If so, how
can this modelling be adapted to include newly developed drugs?
2. How do batch RL algorithms compare in terms of outcomes when applied to the
HIV drug scheduling problem? Are the drugs recommended by the batch RL
algorithms consistent with the strategies currently in place for a particular real
patient?
3. Does applying a particular batch RL algorithm improve patient wellness for sim-
ulated patients?
4. How do the batch RL algorithms under consideration compare in performance
when applied to benchmark domains?
4.4 Research methodology
This research has been completed in a number of phases. The initial phase focused pri-
marily on gathering real HIV patient data from hospitals in Johannesburg and preparing
this data for testing purposes. The next phase involved simulating HIV patient data
using a mathematical model in MATLAB. We discuss the details of this model and
the simulated data in the next section. After collecting and generating the necessary
data, the HIV drug scheduling problem was formulated as an MDP. This involved con-
structing a suitable reward function for the real data case and choosing relevant state
variables from the data available. This reward function should ultimately reward those
situations in which a patient’s health shows an adequate improvement under a par-
ticular drug combination and penalize those that do not. For the simulated case, we
are restricted to constructing the MDP in the same way as Adams et al. (2004). We
discuss the details of this MDP construction in Section 4.5.2. Once the construction
of the MDP was completed, each of the batch RL techniques under consideration was
implemented in MATLAB. A brief description of the implementation is provided in the
final section of this chapter. The code was tested on both the real and simulated data
sets. These results and the resources used for testing purposes are given in Chapter 5.
Finally, data sets for the mountain car and acrobot domains were generated using the
dynamics provided in Appendix A.1 and A.2. These data sets were also used to test
relative performances of the learning techniques.
4.5 Data collection and simulation
This research required us to use both real and simulated data for training and testing
purposes. Simulated data can be generated to determine algorithmic performance on
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large scales. We can also apply the policies learned by the algorithms back to the model
used for data generation to generate more samples and see whether these samples ex-
hibit any improvement. That is, we can determine whether the policies learned by the
algorithms result in improved health among the patients generated according to the
model. Availability of real data is limited hence resulting in a much smaller sample set.
However, this real data contains much more specific drug information for each patient.
This information is crucial for determining the suitability of specific drug combinations
in a real context rather than a generalized prediction of what combinations of drug
classes can be useful. We can draw comparisons between the drug combinations sug-
gested by the algorithms and the drug combinations currently in place. The subsequent
sections discuss how data has been collected and simulated for this research.
4.5.1 HIV patient data collection
We would like to express our thanks to the staff of the Charlotte Maxeke Johannesburg
Academic Hospital and Dr Minakshi Jivan for assisting us in the collection of patient
data. All patient data has been collected having obtained ethics clearance and is in
compliance with the rules stipulated by the Human Research Ethics Committee at the
University of the Witwatersrand.1
The data of 250 HIV-infected patients comprising of CD4+ counts, viral loads and
drug therapy was collected from a period of up to ten years to produce a set of 2 560 sam-
ples in total. Patient selection was entirely random and based on limited data sources.
Data preprocessing and reasons for examining these specific variables are discussed in
Section 4.6.2 where we formulate an MDP for the real-world HIV drug scheduling prob-
lem.
4.5.2 Simulating HIV patient data using a mathematical model
We introduce the mathematical model we used to generate artificial HIV data for exper-
imentation. In general, modelling HIV infection and its impact on the immune system
requires many factors to be considered; despite the existence of complex interactions
between many biological components, only a small subset of these biological indicators
can be chosen for modelling. For the purposes of this research generating suitable HIV
patient data requires using a model of the HIV infection dynamics that includes pa-
tient wellness indicators that adequately describe a patient’s condition at a particular
time. These indicators can in turn be used to model the HIV domain as an MDP and
constitute the state space for the reinforcement learning problem. Perhaps the most
obvious choice of a wellness indicator for an HIV-infected individual is the viral load;
this is a direct measure of the number of HIV particles contained in the blood. The
HIV viral load is measured as the number of copies of RNA per millilitre of blood.
Other indicators that can be used to determine the health of an HIV-infected individual
include the numbers of infected and uninfected CD4+ cells and macrophages. Immune
1These rules specify the maintenance of strict patient confidentiality
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effectors such as CD8+ cells, can be used as an indicator of the body’s immune response
to the presence of infected T-cells and the pathogen itself. Ideally, a suitable HIV data
generation model should at minimum take these wellness indicators into account.
A model used to simulate HAART in HIV-infected patients should also include
the action of commonly used antiretrovirals and allow for the use of multiple drug
combinations at each time. Ideally, we wish to use a model that accounts for specific
drug combinations such as the popular EFV, FTC, tdf combination (now being sold as
Atripla), however this is unrealistic, so we settle for a model that simulates action of the
major classes of antiretroviral drugs instead. Unfortunately this means that the action
of one member of a particular drug class is considered to be identical to another member
of the same class which is not always the case and is something we would ideally like to
determine.
The model we used to simulate HIV data under HAART is based on work from
Callaway & Perelson (2002). The model itself may be found in Adams et al. (2004)
and Adams et al. (2005). While it was originally constructed to take into account
possible treatment interruptions in HAART, here we ignore the case when patients
are completely removed from medication. The complete dynamics of the model are
described by the set of Equations 4.5.1 - 4.5.6.
dT1
dt
= λ1 − d1T1 − (1− 1)k1V T1 (4.5.1)
dT2
dt
= λ2 − d2T2 − (1− f1)k2V T2 (4.5.2)
dT ∗1
dt
= (1− 1)k1V T1 − δT ∗1 −m1ET ∗1 (4.5.3)
dT ∗2
dt
= (1− f1)k2V T2 − δT ∗2 −m2ET ∗2 (4.5.4)
dV
dt
= (1− 2)NT δ(T ∗1 + T ∗2 )− cV − [(1− 1)ρ1k1T1 + (1− f1)ρ2k2T2]V
(4.5.5)
dE
dt
= λE +
bE(T
∗
1 + T
∗
2 )
(T ∗1 + T ∗2 ) +Kb
E − dE(T
∗
1 + T
∗
2 )
(T ∗1 + T ∗2 ) +Kd
E − δEE (4.5.6)
Here, T1 (T
∗
1 ) denotes the number of non-infected (respectively infected) CD4
+ T-
lymphocytes (in cells/ml), T2 (T
∗
2 ) the number of non-infected (respectively infected)
macrophages (in cells/ml), V the number of free HI viruses (in copies/ml) and E the
number of cytotoxic T-lymphocytes (in cells/ml). The values of the various parameters
of the model are taken directly from Adams et al. (2004) and Bonhoeffer et al. (2000).
These are listed in Table 4.1.
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Parameters Value Units Description
λ1 10 000
cells
ml.day production rate of CD4
+ cells
d1 0.01
1
day death rate of CD4
+ cells
1 ∈ [0, 1) - efficacy of RTI
2 ∈ [0, 1) - efficacy of PI
k1 8.0× 10−7 mlvirions.day infection rate of CD4+ cells
λ2 31.98
cells
ml.day production rate of macrophages
d2 0.01
1
day death rate of macrophages
f 0.34 - reduction of treatment efficacy for macrophages
k2 1.0× 10−4 mlvirions.day infection rate of macrophages
δ 0.7 1day death rate of infected cell
m1 1.0× 10−5 mlcells.day immune-induced clearance rate for CD4+ cells
m2 1.0× 10−5 mlcells.day immune-induced clearance rate for macrophages
NT 100
virions
cell virions produced per infected cell
c 13 1day natural death rate of virus
ρ1 1
virions
cell average number of virions infecting a CD4
+ cell
ρ2 1
virions
cell average number of virions infecting a macrophage
λE 1
cells
ml.day production rate of immune effector/cytotoxic T-cell
bE 0.3
1
day maximum birth rate for cytotoxic T-cell
Kb 100
cells
ml saturation constant for cytotoxic T-cell birth
dE 0.25
1
day maximum death rate for cytotoxic T-cell
Kd 500
cells
ml saturation constant for cytotoxic T-cell death
δE 0.1
1
day natural death rate of cytotoxic T-cells
Table 4.1: Parameters used in Equations 4.5.1 – 4.5.6 (Adams et al., 2004).
The model consists of two populations of target cells representing CD4+ T-cells and
macrophages respectively (Adams et al., 2004). In particular, the classes of RTIs and PIs
are modelled. The manner in which NRTIs and NNRTIs operate is largely similar hence
they are grouped together as one class of drug. Like most other mathematical models of
HIV-infection under HAART, the model includes parameters for the drug efficacy of each
class of ARV under consideration. These parameters are 1 and 2. They describe how
effective the RTI and PI classes of drugs are in reducing infection respectively (Adams
et al., 2004). The model assumes that the RTI class of drugs is more effective in the
CD4+ population of cells than in macrophages where the efficacy is reduced by a factor
of f , f ∈ [0, 1]. The PI class of drugs is only included in equations describing the change
in the viral load under HAART, since these drugs operate by directly interfering with
the formation of viral proteins that are necessary for viral production. Infected T-cells
result from direct interaction between uninfected T-cells and free virus particles; these
cells are removed from the system via natural death or through the action of cytotoxic
T-cells. The model assumes both T-cells and macrophages have the same death rates,
d1 = d2. The immune effector cells are produced in response to the presence of infected
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cells and existing immune effectors. The action of these immune effector cells triggers
lysing of infected T-cells and macrophages which results in their removal from the system
of equations at the rates of m1 and m2 respectively. The rate at which the virus infects
both types of cells is assumed to be different and is given by the parameters k1 and
k2 respectively. Free virus particles are produced by both infected macrophages and
infected T-cells; the model assumes these are produced at the same rate.
Adams et al. (2004) demonstrate that when both 1 and 2 are zero, the dynamic
model has three physical equilibrium points where all the variables are non-negative.
These equilibria are:
(T1, T2, T
∗
1 , T
∗
2 , V, E) = (10
6, 3 198, 0, 0, 0, 10), (4.5.7)
(T1, T2, T
∗
1 , T
∗
2 , V, E) = (967 839, 621, 76, 6, 415, 353 108), (4.5.8)
(T1, T2, T
∗
1 , T
∗
2 , V, E) = (163 573, 5, 11 945, 46, 63 919, 24). (4.5.9)
Note that Equation 4.5.7 is an unstable equilibrium point representing an uninfected
individual; Equations 4.5.8 and 4.5.9 are the stable equilibrium points representing
an infected individual. Specifically, Equation 4.5.8 represents an individual with good
immune control over the virus. This individual has a low viral load and high CD4+
and CD8+ counts; a patient is considered to be in a healthy steady state or stationary
equilibrium here. Equation 4.5.9 represents an individual in an unhealthy steady state
whose viral load is considerably elevated and T-cells are in short-supply in the absence
of treatment.
Using this dynamic model, we generate HIV data in the same way as Ernst et al.
(2006). That is, we assume the variables T1, T2, T
∗
1 , T
∗
2 , V and E are measured every
five days and each patient is monitored for a period of 1 000 days. We consider 50
patients in the infected unhealthy steady state and randomly select medication for the
patient every five days. The values of 1 and 2 are modified according to whether the
associated class of drug is in use. Using Euler’s method to solve the system of equations,
the resulting T-cell counts, macrophage counts and viral load are recorded. In this way,
each patient produces 200 samples. For a total of 50 patients, 10 000 samples are
generated. In Chapter 5, we consider a number of experiments using this simulated
data. Some of these experiments require larger sample sets to be used, or require us to
generate more samples of data iteratively after applying RL to the problem domain; we
discuss this iterative data generation procedure in Chapter 5 where necessary.
4.6 Modelling the HIV drug scheduling problem as an
MDP
In this section we formulate the HIV drug scheduling problem as an MDP to which the
RL techniques under consideration can be applied for learning purposes. We distinguish
between different MDPs for the simulated data and real data cases respectively as some
of the variables modelled by Equations 4.5.1 - 4.5.6 are not directly observable in reality.
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4.6.1 An MDP formulation for the simulated case
For the case of simulated data, we have modelled the HIV drug scheduling problem as a
MDP in a manner almost identical to Ernst et al. (2006). Here our state space S consists
of six state variables corresponding to the number of healthy CD4+ T-cells (T1), healthy
macrophages (T2), infected CD4
+ T-cells (T ∗1 ), infected macrophages (T ∗2 ), free virus
particles (V ) and cytotoxic T-cells (E) respectively. Our action space A is comprised
of three actions representing the possible drug combinations available. That is, at each
time step, we consider one of three on-off drug combinations. These are:
1. Use both RTI and PI class drugs
2. Use only an RTI
3. Use only a PI
Note that we have ignored the case when both classes of drugs are turned off since this
is the equivalent of cycling a patient off drugs completely and constitutes a treatment
interruption. As mentioned in Section 2.6.3 of Chapter 2, intermittent therapy has
proven dangerous under the SMART trial. Unfortunately we are limited to examining
only two classes of drugs here because of the manner in which HIV-infection has been
modelled.
Like Ernst et al. (2006), we are looking for those drug strategies that minimize the
cumulative instantaneous costs of taking various drug combinations over an infinite time
horizon. Here the instantaneous cost of taking a particular drug combination at a time
t is calculated according to
c(st, at) = QVt +R11t
2 +R22t
2 − SEt (4.6.1)
where Q = 0.1, R1 = 20 000, R2 = 2 000 and S = 1 000. The variables Vt and Et
represent the number of free virus particles (copies/ml) and cytotoxic T-cells (copies/ml)
at time t respectively. The parameters 1t and 2t correspond to the efficacies of the
RTI and PI under consideration at time t respectively. When an RTI is being used for
treatment, 1t = 0.7; when a PI is being used, 2t = 0.3; otherwise, these values are
0. Intuitively, a combination of drugs that results in a raised viral load increases the
cost function; conversely, taking a combination of drugs that results in a better immune
effector response, decreases the cost function. The cost function may be viewed as
an inverse reward function. That is, a higher cost would be the equivalent of a lower
reward in the context of RL and would result in the agent being penalized for taking
the associated action. The interested reader should refer to Adams et al. (2004) and
Adams et al. (2005) for the precise reasoning behind this cost function for the system
of Equations 4.5.1 - 4.5.6.
4.6.2 An MDP formulation for the real data case
Moving from the simulated case to dealing with real data sets requires us to consider
a number of issues pertaining to the data available. Firstly, when simulating how HIV
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interacts with a group of patients, each patient is assumed to have the same dynam-
ics. When using real data, this is not necessarily the case since the dynamics may
vary significantly from patient to patient. Reasons for differing dynamics can often
be attributed to existence of different HIV types and strains or differences in patients’
immune systems. A possible means of addressing this issue is to consider including an
attribute such as the HIV type or specifics regarding a patient’s case in the state space.
In our research, we have tried to eliminate differences that result from varying types
of HIV by considering only those patients infected by HIV-1. We restrict our study to
HIV-1 since our sources of HIV data are limited and HIV-2 is not prevalent in South
Africa. However, because of the large number of clades in HIV-1, this is not necessarily
the best solution as variation between individual strains of HIV is still unaccounted for.
In an ideal situation, it might be useful to consider adding a state variable for the HIV
strain to the Markov model. With restrictions to the data we have access to, this was
not possible.
One of the issues associated with using real data is defining a time step for modelling
an MDP. In the simulated case, we can assume that the values of the state variables
determined according to the system of ODEs 4.5.1 - 4.5.6 are recorded at regular time
steps that are equidistant from one another. For real data, patients are typically required
to visit the hospital for blood tests every six months however, this does not always
happen. To overcome this issue, we have defined a single time step to be a period
of six months from the previous date of visit and interpolated the values of the state
variables from the data where regular six-month data was unavailable. In addition,
we have normalized all state variables using a logarithmic transformation. Reasons for
normalizing the real data are based on the fact that it is easier to define a reward function
on reduced data range. This problem does not exist when using simulated data since
we use the same cost function as defined by Ernst et al. (2006). There are also several
cases in the real data set where the values of the state variables are larger than those
in the simulated data set, despite being expressed in the same units. Normalization is
useful for these cases. The values of the state variables are all plotted on a logarithmic
scale in both the experimentation using simulated and real data sets. This is for easier
visualization and interpretation.
Perhaps the most significant challenge that arises when using real data is the problem
of partial observability (Ernst et al., 2006). In the simulated case, we assumed that all
the state variables can be observed and recorded directly with current technology. In
reality however, this is not the case: current blood tests conducted by hospitals for HIV-
infected individuals do not measure macrophage counts and existing technology cannot
distinguish between infected and uninfected CD4+ T-lymphocytes; in addition, CD8+
lymphocytes are only recorded once in a few years if at all. With these limitations in
available data, we are forced to consider only the CD4+ count and viral load data when
constructing a state space for the MDP.
Having discussed the major difficulties when using real data for training, we can
formally define how we have constructed an MDP for the real data case. Our state
space S consists of a patient’s CD4+ T-cell count (T ) and viral load (V ) normalized by
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applying a logarithmic transform. Unlike when using simulated data that was generated
according to a model that could not take into account specific drugs, for real data we
consider seven major drugs that are currently used in South Africa in ARV treatment.
These are EFV, 3TC, tdf, d4T, LPV/r, NVP and AZT.2 Reasons for restricting our
study to these seven drugs are based on the fact that these drugs are widely available
in the country and are commonly used; another major reason is the real patient data
we have accessed makes use of combinations of these drugs. We can represent the seven
drugs under consideration as a seven-tuple vector of binary values where each value
corresponds to whether the associated drug is being used at a certain time or not.
This seven-tuple vector represents the action taken by a patient at a particular time.
Theoretically, our action space A consists of 128 possible actions based on the drugs
being used in a multi-drug combination. Practically, certain combinations of drugs are
not taken together because of the side-effects they may produce when combined, and
since this research does not consider the use of STIs, we do not allow for the possibility
of a patient not receiving any treatment. By taking this into consideration, we can
eliminate a few actions from the action space. While we have only considered the use
of these seven drugs, it is possible to extend the action space to include more drugs
or newly developed drugs for a clinical trial setting. In the case of clinical trials, the
patient data obtained from a particular phase of the trials can be used to train the batch
RL algorithms we consider in this research; here, the action space would include the
developed drug. Results from using batch RL algorithms between phases of a clinical
trial could provide medical researchers with insight into the efficacy of the new drug(s)
fairly quickly before the subsequent phase begins. This is particularly useful since
phases of a clinical trial are usually very lengthy and typically last a number of years.
We are aware that the action space is exponential in the number of drugs considered,
however there are ways in which this problem can be overcome. Subtle variants of the
fitted Q-iteration method exist that demonstrate how the algorithm can be extended to
large and/or continuous action spaces. These procedures are discussed by Antos et al.
(2007) and briefly by Ernst et al. (2005). The same can be said for LSPI (see Pazis &
Lagoudakis (2011) for details).
Like Zhao et al. (2009), we use a composite function to define the reward the agent
receives at each time step during learning. This reward function is comprised of two
functions, rt1 and rt2, based on the changes observed in a patient’s T-cells and viral
loads respectively. We penalize an increase in the viral load or decrease in the CD4+
count. We give a large positive reward when a patient’s viral load is below detectable
limits i.e. less than 40 copies/ml (Vt = -1). If a patient’s T-cell count neither decreases
nor increases, we do not give a reward since there is no change in immune response.
However, if the viral load stays the same, we give a penalty of -1. This assists in making
the algorithms learn to choose those actions which improve the viral load as quickly as
possible. The values for rt1 and rt2 are given by,
2We consider LPV and r together since LPV must be taken in conjunction with r.
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rt1 =

5, if Tt > Tt−1
−5, if Tt < Tt−1
0, otherwise
(4.6.2)
rt2 =

5, if Vt < Vt−1 and Vt 6= −1
−5, if Vt > Vt−1 and Vt 6= −1
25, if Vt = −1
−1, otherwise.
(4.6.3)
Here, the time step t is a period of 6 months between patient visits to the hospital. The
final reward is given by the following equation:
rt = rt1 + rt2. (4.6.4)
In this form, we place equal emphasis on both state variables. It would, however,
be possible to introduce weights to this sum if we wanted one variable to have more
influence on the actions selected than the other.
4.7 Implementation of batch reinforcement learning tech-
niques
For this research, all algorithms and data generation methods have been implemented in
MATLAB. For comparative purposes all learning algorithms need to be implemented in
the same language. We chose MATLAB primarily because of its Neural Network Tool-
box that allows us to create and customize neural networks easily for the neural fitted
Q-iteration algorithm. Data visualization is also fairly straightforward since MATLAB
has an extensive set of graphics options available to the user. Furthermore, matrix
manipulation is important for methods such as LSPI; MATLAB is particularly good at
this.
For the fitted Q-iteration with extra trees algorithm, we chose to represent each tree
as a four-tuple (f1, f2, f3, f4) where the first element of the tuple corresponds to the
attribute selected at the root node to split on; the second element corresponds to the
value of the split, and the third and fourth elements represent the index of the left and
right subtrees respectively. Each of the subtrees produced were represented in the same
way. In this way, a tree could easily be represented recursively.
Coding the neural fitted Q-iteration method consisted of executing the standard
fitted Q-iteration algorithm using neural networks to perform the regression step. Our
specific implementation used the resilient backpropagation algorithm (RPROP) (Ried-
miller & Braun, 1993) to train the network. RPROP is an improved version of classical
backpropagation method that is used to train neural networks. The main advantage
of using RPROP is the performance gain. This gain is largely a result of the manner
in which weights are updated during training: weights are updated by combining the
current gradient and the gradient from the previous step in training (Hatzigeorgiou &
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Megraw, 2006). Network structures were varied according to the specific experiment
performed.
Implementation of the LSPI algorithm mainly involved coding methods for calcu-
lating suitable basis functions for the problem at hand. We have used Gaussian radial
basis functions which we mention in the next chapter. These basis functions were used
by the LSPI algorithm to perform standard matrix multiplication and derive a suitable
policy for the domain of interest. While it is possible for tilings to be used for the same
purposes, preliminary testing revealed that Gaussian radial basis functions performed
better across all the domains we considered.
4.8 Conclusion
In this chapter, we presented the methodology that was carried out to complete this
research. This involved formulating the drug scheduling task as an MDP, collecting and
generating patient data, cleaning the data, and applying the learning techniques under
consideration to these data sets. The next chapter presents the results obtained from
each of the experiments conducted and a discussion of what these results mean for drug
scheduling in the HIV domain.
Chapter 5
Results and Discussion
5.1 Introduction
In this chapter we present the major results of this research. We begin by providing
the specifications of the machine we have used for testing purposes in Section 5.2. In
Section 5.3, we examine the performance of each of the batch reinforcement learning
techniques discussed in Chapter 3 on the benchmark domains of mountain car and the
swing-up acrobot. Specifically the results from the benchmark domains can give us some
insight as to how the algorithms perform on well-behaved domains. In Section 5.3, we
apply the same techniques to the set of simulated data that was discussed in Chapter 4.
We use each of the policies determined on this set of simulated data to generate more
patient samples for learning in Section 5.4; these samples allow us to ascertain whether
the learned policies result in improved patient outcomes for the simulated case. When
experimenting using real data, it is not possible to implement the policies suggested
by the algorithms on real patients and observe the outcomes. For these reasons, we
perform a match test, to observe how many times the suggested policy matches those
policies currently in place from the patient data available. These results are provided
in Section 5.5. Section 5.6 concludes the chapter by discussing how the results obtained
in this chapter can be used to answer the research questions formulated in Chapter 4.
5.2 System specifications
We have used MATLAB 7.11 (R2010b) to implement all of our code for this research.1
All experimentation has been performed on a MacBook Pro ’11 with the following
specifications:
• Mac OS X Lion Version 10.7.5 (11G63b)
• 2.66 Ghz Intel Core 2 Duo
• 4GB 1067 MHz DDR3
1All the code written for this research is available upon request at sonali.parbhoo@students.wits.ac.za.
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• 3MB Cache
5.3 Benchmark domain experimentation
In this section, we present the results of the performances of each batch RL technique
when applied to the benchmark domains of the mountain car and acrobot task respec-
tively. Specifically, we examine how the algorithms compare in terms of their run times
for data sets of differing sizes as well as their outcomes in terms of the policies they
determine.
5.3.1 Performance assessment metrics
In order to compare the performances of each batch RL technique under consideration
when applied to the benchmark domain tasks, we require certain metrics to assess
the quality of the policies determined. In our case, we use (i) the number of times a
successful optimal policy2 is generated and (ii) how quickly the learning task at hand
is fulfilled under a successful optimal policy. The former requires us to run a number
of trials on different sample sets and determine what percentage of these trials produce
a policy that accomplishes the task. The latter requires us to assess how many steps
are required to fulfill a certain task under a successfully computed optimal policy. The
learning technique that reaches the goal state most often and/or requires the smallest
number of steps to reach the goal state exhibits the best performance overall.
5.3.2 Comparison of algorithmic outcomes for mountain car
In this experiment we compare the outcomes of each batch RL technique under consid-
eration when applied to the mountain car task. Specifically, we divide the experiment
into three parts. Part (i) is based on comparing the run time performances of each
algorithm when applied to sets of mountain car samples of varying sizes. We acknowl-
edge using code by Fonteneau (2009) for generating these mountain car samples. In
particular, we have generated sample sets of sizes 5 000, 10 000, 15 000, 20 000, 25 000
and 30 000 respectively. Each episode within the set of samples begins at the initial
state (p, v) = (-0.5, 0) representing a stationary car at the bottom of a hill; an episode
ends once the car reaches the top of the hill or if either p < -1 or v leaves the interval
[-3, 3]. We execute 50 iterations of each learning technique and measure the time it
takes for each method to reach completion. This is repeated over a set of five trials
from which we can obtain an average run time. While run time is not an indicator of
the quality of the solution obtained, it is of practical significance if the batch of samples
available is quite large. It can also give us an indication about the performance of each
method relative to the training time required. In part (ii), we determine the optimal
policy from the start state at the bottom of the hill for each algorithm using a sample
2Hereafter, we use the term optimal policy to refer to the approximate optimal policy after N -steps,
pi∗N .
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set of 10 000 samples after 50 iterations and illustrate these results. In part (iii), we
first execute each algorithm on 30 sample sets each containing 10 000 samples. For each
of the algorithms, we determine an optimal policy after 50 iterations. From the opti-
mal policies determined, we calculate the percentage of policies that are successful in
reaching the goal state. Thereafter, we select 10 sample sets for which all three learning
methods are able to produce successful policies. We record the number of steps taken
to reach the goal under pi∗50 from the learning techniques across each of the 10 sample
sets. Each part of this experiment has been performed using sample sets that are gen-
erated according to a random policy. We use the parameters M = 50 and nmin = 2
for fitted Q-iteration with extra trees. A neural network consisting of 4 input nodes, a
layer of 50 hidden nodes and 1 output node are used for neural fitted Q-iteration.This
neural network structure has been chosen after significant testing. For LSPI, we use 100
randomly centered Gaussian radial basis functions with σ2 = 5. We present the results
for (i) - (iii) hereafter.
(i) Run time comparison of learning techniques using sample sets of varying
sizes
Tables 5.1 - 5.3 show the running times of the three batch RL techniques under consid-
eration for sample sets of varying sizes. The average of these times are computed over
5 trials.
|F| 1 2 3 4 5 Average time (mins)
5 000 12.38 15.81 16.19 16.73 14.62 15.15
10 000 55.76 51.87 46.38 49.29 52.71 51.20
15 000 55.83 56.92 48.27 44.02 62.50 53.51
20 000 61.46 48.97 57.91 63.82 67.25 59.89
25 000 66.70 68.79 89.12 59.32 64.81 69.75
30 000 69.71 63.14 78.72 78.93 83.95 74.89
Table 5.1: Run times of neural fitted Q-iteration on mountain car sample sets of varying
sizes over 5 trials.
|F| 1 2 3 4 5 Average time (mins)
5 000 98.72 102.49 116.27 99.36 108.58 105.08
10 000 126.34 120.10 132.74 121.67 121.23 121.42
15 000 136.00 138.21 131.29 131.03 137.96 134.90
20 000 138.71 142.11 139.43 139.82 139.41 139.67
25 000 148.33 141.71 144.00 148.39 148.52 146.19
30 000 145.67 152.71 148.88 149.72 147.19 148.83
Table 5.2: Run times of fitted Q-iteration using extra trees on mountain car sample sets
of varying sizes over 5 trials.
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|F| 1 2 3 4 5 Average time (mins)
5 000 3.18 3.19 3.24 3.11 3.07 3.16
10 000 6.36 6.42 6.79 7.02 6.21 6.56
15 000 10.11 9.59 9.71 10.28 9.02 9.74
20 000 12.45 12.92 11.63 12.22 11.73 12.19
25 000 18.31 18.76 19.20 16.72 18.19 18.24
30 000 24.26 24.19 24.18 23.72 24.84 24.24
Table 5.3: Run times of LSPI on mountain car sample sets of varying sizes over 5 trials.
Figure 5.1: Average run times of each algorithm when applied to the mountain car task
using sample sets of varying sizes.
The run times of each algorithm increase with an increase in the size of the sample sets
used for learning as is expected. For both versions of fitted Q-iteration, the majority
of the time is spent on the regression step to determine a Q-function of approximation.
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That is, for the fitted Q-iteration algorithm with extra trees, we spend the most time
actually constructing the ensembles of trees recursively; for neural fitted Q-iteration,
most time is spent training the neural network. The major computational step for LSPI
involves computing the basis functions for each pair state (p, v). Overall, the extra
trees implementation is extremely slow in comparison to the other two methods. LSPI
outperforms the other two methods significantly in terms of its run time. This is based
on the fact that once the basis function calculation step of the algorithm is complete, the
Q-values can be determined from a straightforward matrix multiplication step. Figure
5.1 shows a summary of these times for each algorithm as the size of the sample set
used for learning increases. While changing the parameters M and nmin would result
in significantly different performances, Ernst et al. (2005) demonstrate that M = 50 is
large enough to ensure that the accuracy of the models produced for this domain cannot
be improved further by increasing the number of trees. Hence we have chosen the same
parameter values for this experiment.
(ii) Optimal policies determined by batch RL techniques for mountain car
task.
In this part of the experiment, we determine an optimal policy from the start state (p, v)
= (-0.5, 0) for the mountain car task. To do so, we run 50 iterations of each learning
technique on a sample set of 10 000 randomly generated mountain car samples. Figures
5.2, 5.3 and 5.4 give a representation for the optimal policy after a different number of
iterations, N . The points in blue correspond to those states where Q̂N ((p, v),−4) >
Q̂N ((p, v), 4); the points in red represent states where Q̂N ((p, v),−4) < Q̂N ((p, v), 4);
points in green correspond to states where Q̂N ((p, v),−4) = Q̂N ((p, v), 4).
We observe that for the particular sample set used, each algorithm is able to generate
a successful policy however, the policies obtained differ slighty. Results from NFQ
show that the policy changes quite remarkably between iterations (see Figure 5.2 (a) -
(e)). The policies obtained using fitted Q-iteration with extra trees and LSPI tend to
stabilize and change less frequently at some point (see Figures 5.3 and 5.4 (a) - (e)).
The trajectory obtained from applying the optimal policy from LSPI to the start state
(p, v) = (-0.5, 0) is longer than the trajectories obtained from applying fitted Q-iteration
and neural fitted Q-iteration to the same sample set. Both versions of fitted Q-iteration
are able to determine similar optimal policies that are more efficient since they require
fewer and smaller steps to reach the goal state. For the particular sample set used here,
neural fitted Q-iteration produces the most effective trajectory to the goal state using
only 21 steps in comparison to the 24 steps and 40 steps required by fitted Q-iteration
with extra trees and LSPI respectively. This is shown in Figure 5.2 (f).
We note that applying the learning techniques to this sample set has produced a
successful optimal policy for each case. However, since an episode in the mountain car
task ends either when the goal state is reached, or when p < -1 or v leaves the interval
[-3, 3], it is possible to obtain an unsuccessful policy when using other sample sets.
Figure 5.5 shows an example of a trajectory produced by an unsuccessful policy where
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the position of the car, p < −1. In addition, it is possible that one learning method
outperforms the others on a particular sample set, but not in general. For these reasons,
we perform part (iii) of this experiment.
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(a) arg maxa∈A Q̂10(s, a) (b) arg maxa∈A Q̂20(s, a)
(c) arg maxa∈A Q̂30(s, a) (d) arg maxa∈A Q̂40(s, a)
(e) arg maxa∈A Q̂50(s, a) (f) Trajectory from initial state s0 = (−0.5, 0)
Figure 5.2: (a) - (e): Graphical representation of optimal policy, pi∗N , after N steps of
neural fitted Q-iteration, where N = 10, 20, 30, 40 and 50 respectively. (f): Trajectory
from s0 = (−0.5, 0) under policy pi∗50.
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(a) arg maxa∈A Q̂10(s, a) (b) arg maxa∈A Q̂20(s, a)
(c) arg maxa∈A Q̂30(s, a) (d) arg maxa∈A Q̂40(s, a)
(e) arg maxa∈A Q̂50(s, a) (f) Trajectory from initial state s0 =
(−0.5, 0)
Figure 5.3: (a) - (e): Graphical representation of optimal policy, pi∗N , after N steps of
fitted Q-iteration with extra trees, where N = 10, 20, 30, 40 and 50 respectively. (f):
Trajectory from s0 = (−0.5, 0) under policy pi∗50.
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(a) arg maxa∈A Q̂10(s, a) (b) arg maxa∈A Q̂20(s, a)
(c) arg maxa∈A Q̂30(s, a) (d) arg maxa∈A Q̂40(s, a)
(e) arg maxa∈A Q̂50(s, a) (f) Trajectory from initial state s0 = (−0.5, 0)
Figure 5.4: (a) - (e): Graphical representation of optimal policy, pi∗N , after N steps of
LSPI, where N = 10, 20, 30, 40 and 50 respectively. (f): Trajectory from s0 = (−0.5, 0)
under policy pi∗50.
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Figure 5.5: Example of the trajectory resulting from an unsuccessful policy on the
mountain car domain.
(iii) Number of steps to goal state of mountain car task for each learning
technique
For the final part of this experiment, we record the number of successful policies pro-
duced by each learning technique after 50 iterations when applied to 30 sample sets of
10 000 samples each. From these 30 sample sets, we select 10 sample sets which allow
for a successful optimal policy to be computed across all three learning techniques. We
compute the average number of steps to reach the goal state from the initial state for
each method.
Table 5.4 gives the number of times the learning technique considered produces a
successful policy over 30 sample sets.
NFQ FQI LSPI
Number of successful policies 21 28 23
% success 70.00 93.33 76.67
Table 5.4: Number of successful policies computed under each learning technique over
30 sample sets.
In Table 5.5 we record the number of steps required to reach the goal state for each
batch learning method over 10 sample sets or trials and compute an average.
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Trial Steps taken by NFQ Steps taken by FQI Steps taken by LSPI
1 23 20 36
2 19 35 40
3 174 21 92
4 40 16 61
5 39 32 67
6 27 29 69
7 138 21 78
8 273 22 105
9 46 22 73
10 20 24 40
Average 79.90 24.20 66.10
Table 5.5: Number of steps taken by each algorithm to reach goal state under optimal
policy over 10 trials.
5.3.3 Discussion of results for mountain car domain
Results from experimentation on the mountain car task demonstrate that each learning
method has its own associated advantages and disadvantages. In terms of speed, LSPI
and neural fitted Q-iteration are both significantly faster than the extra trees version of
fitted Q-iteration. This is a direct consequence of the function approximation structure
that is used for each technique. For the particular set of samples used in part (ii) of
this experiment, the trajectories obtained as a result of the optimal policy demonstrate
similar performance between both versions of fittedQ-iteration. The resulting trajectory
produced by applying LSPI to the same set of samples, is almost double in length. This
means that for the sample set used in part (ii), it takes LSPI significantly longer to reach
the goal state than neural fittedQ-iteration and fittedQ-iteration with extra trees. From
part (ii), we would expect similar results when applying each of the learning methods
to different sample sets in part (iii). However, this is not necessarily the case. While
fitted Q-iteration with extra trees and neural fitted Q-iteration are essentially variations
of the same learning technique, the extra trees implementation is far superior in terms
of the number of successful policies it is able to produce. In fact, despite the results
from part (ii), LSPI is able to generate an optimal policy with a higher success rate
than neural fitted Q-iteration, regardless of the length of the resulting trajectory. These
results are reinforced by the fact that when we apply all three learning methods to sets of
samples that generate successful policies in each case, neural fitted Q-iteration tends to
produce trajectories that vary considerably in length. In some instances, the trajectories
are much shorter than those produced by LSPI and FQI with extra trees whereas in
other cases, the opposite is true. This means that neural fitted Q-iteration produces
trajectories that are on average longer than those produced by both other techniques.
Overall, the performance of neural fitted Q-iteration is somewhat unpredictable and
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largely dependent on the sample set used. A possible explanation is that the neural fitted
Q-iteration algorithm may require more iterations to be run to refine its approximation
of the Q-function adequately enough. In our experimentation, we have run 50 iterations
using each method however, the number of iterations required to converge to an optimal
Q-function may be significantly different for each method. This is further demonstrated
by (a) - (e) in Figure 5.2 where the policy differs significantly between iterations. In
contrast, the optimal policies for LSPI and fitted Q-iteration with extra trees remain
largely stable after 20 iterations (see Figures 5.3 and 5.4 (a) - (e)). It is also possible
that a better neural network structure is required. In general, despite its speed, fitted
Q-iteration using extra trees tends to produce the most effective optimal policy that
results in a trajectory with the shortest number of steps.
5.3.4 Comparison of algorithmic outcomes for swing-up acrobot
This experiment is more or less identical to the experiment performed on the mountain
car task that was discussed in the previous section. We have generated samples starting
from the initial state (θ1, θ2, θ˙1, θ˙2) = (0, 0, 0, 0) representing the acrobot lying in
the vertical position using a random policy. In part (i), we compare the run time
performances of neural fitted Q-iteration, fitted Q-iteration and LSPI on sample sets
of sizes 5 000, 10 000, 15 000, 20 000, 25 000 and 30 000 respectively. At each time
step in an episode within the set of samples, we choose a random action from the set
of 3 possible actions {−1, 0, 1}. These actions correspond to the torque applied to the
second joint of the acrobot. An episode reaches completion once the acrobot is able to
swing its tip above the first joint by an amount equal to the length of its links which
in this case is 1. That is, the acrobot reaches its goal state when its tip lies above a
height of 1. As with the mountain car task, we execute 50 iterations of each learning
technique and measure the time it takes for each method to reach completion. The test
is repeated over five trials from which an average run time is calculated. In part (ii), we
use a sample set of 10 000 samples to calculate the 50th step optimal policy, pi∗50 under
each learning technique, and compare the outcomes. Finally, in part (iii), we repeat
part (ii) over ten different sample sets each containing 10 000 samples. Here, we obtain
a policy pi∗50, for each method across each sample set. We apply these policies to the
initial state and calculate the number of steps required to reach the goal state for each
sample set. We use the parameters M = 50 and nmin = 2 for fitted Q-iteration with
extra trees. The number of trees is once again adequate to obtain a suitable model of
the data. A neural network consisting of 7 input nodes, one hidden layer of 100 hidden
nodes and 1 output node are used for neural fitted Q-iteration. For LSPI, we use 1 050
randomly centered Gaussian radial basis functions (350 basis functions per action) with
σ2 = 5. We present the results for (i) - (iii) hereafter.
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(i) Run time comparison of learning techniques using acrobot sample sets of
varying sizes
Tables 5.6 - 5.8 show the running times of the three batch RL techniques under consid-
eration for sample sets of varying sizes. The average of these times are computed over
5 trials.
|F| 1 2 3 4 5 Average time (mins)
5 000 25.71 22.19 28.27 24.85 24.93 25.19
10 000 43.15 49.81 54.72 46.11 46.82 48.12
15 000 42.71 48.92 51.47 51.33 51.67 49.22
20 000 49.93 56.49 53.19 53.83 59.71 54.63
25 000 57.96 59.21 63.94 63.60 58.13 60.57
30 000 61.97 65.74 66.81 62.39 65.00 64.38
Table 5.6: Run times of neural fitted Q-iteration on acrobot sample sets of varying sizes
over 5 trials.
|F| 1 2 3 4 5 Average time (mins)
5 000 67.68 72.19 73.47 64.44 71.26 69.81
10000 121.71 121.84 125.92 127.88 123.32 124.13
15 000 129.33 134.45 132.29 132.25 141.73 134.01
20 000 137.21 139.48 145.60 157.83 137.74 143.57
25 000 149.77 149.91 145.38 148.20 148.34 148.32
30000 146.79 141.24 148.17 156.69 169.92 152.56
Table 5.7: Run times of fitted Q-iteration using extra trees on acrobot sample sets of
varying sizes over 5 trials.
|F| 1 2 3 4 5 Average time (mins)
5 000 78.87 73.29 73.81 76.95 68.47 74.28
10 000 105.38 112.31 108.64 108.77 108.90 108.80
15 000 126.98 124.01 124.73 121.35 112.51 121.92
20 000 137.67 139.42 139.28 141.74 140.06 139.63
25 000 148.98 149.20 149.27 149.43 151.72 149.71
30 000 152.29 152.34 150.88 157.46 155.53 153.70
Table 5.8: Run times of LSPI on acrobot sample sets of varying sizes over 5 trials.
The run times of each algorithm increase with an increase in the size of samples sets
used for learning. As before, both versions of fitted Q-iteration spend the most time
calculating the regression step to obtain a suitable Q-function approximation. The
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main computational step for LSPI consists of computing the basis functions for each
state (θ1, θ2, θ˙1, θ˙2). We observe that the extra trees implementation is very slow even
across a different domain. The higher dimensionality of the state space in this case
may contribute to the fact that run times are slower than when using the mountain
car domain as there are more attributes to test and potentially split when using fitted
Q-iteration with extra trees. Neural fitted Q-iteration outperforms both other methods
in terms of speed. LSPI performs significantly slower when applied to the swing-up
acrobot task as opposed to its performance on the mountain car domain. This is a
direct consequence of using a larger number of basis functions to approximate the Q-
values. It is interesting to observe that the average run times of LSPI on the smallest
set of 5 000 samples and the largest set of 30 000 samples are higher than those of
fitted Q-iteration with extra trees. Figure 5.6 shows a summary of these times for each
algorithm as the size of the sample set used for learning increases.
Figure 5.6: Average run times of each algorithm when applied to the swing-up acrobot
task using sample sets of varying sizes.
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Optimal policies determined by batch RL techniques for the swing-up ac-
robot task
Figure 5.7: Policy pi∗50 obtained from applying neural fitted Q-iteration to the swing-up
acrobot task.
Figure 5.8: Policy pi∗50 obtained from applying fitted Q-iteration with extra trees to the
swing-up acrobot task.
Figure 5.9: Policy pi∗50 obtained from applying LSPI to swing-up acrobot task.
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Figure 5.10: Positioning of acrobot at various steps under pi∗50 using neural fitted Q-
iteration.
In this part of the experiment, we determine the 50th step optimal policy from the
start state for the swing-up acrobot task. To do so, we run 50 iterations of each learn-
ing technique on a sample set of 10 000 randomly generated acrobot samples. Be-
cause of the dimensionality of the state space, it is impossible to graphically represent
arg maxa∈A Q̂(s, a) for each pair (s, a) as we did for the mountain car task. Instead, we
provide figures for the positioning of the acrobot at different steps having followed the
policy pi∗50 from the initial state. In particular, Figures 5.10, 5.11 and 5.12 demonstrate
the acrobot at different positions in an episode following learning under neural fitted
Q-iteration, fitted Q-iteration with extra trees and LSPI respectively. The goal states
are indicated. The corresponding sequence of actions taken are given in Figures 5.7, 5.8
and 5.9 respectively. We observe that for this particular sample set, it takes the acrobot
136 steps to reach the goal state using the policy pi∗50 obtained from neural fitted Q-
iteration. For the same sample set, it takes the acrobot 77 steps and 105 steps to reach
the goal state using pi∗50 from fitted Q-iteration with extra trees and LSPI respectively.
If we compare the policies pi∗50 obtained from each learning technique by looking at
the sequence of actions the acrobot takes to reach the goal state, we can see that all
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three policies are very different. The sequence of actions taken by the acrobot having
applied pi∗50 from both versions of the fitted Q-iteration algorithm involve many more
oscillations between applying a torque and applying a torque in the opposite direction.
As a result, we see the acrobot swinging back and forth more rapidly. This is not the
case when using the LSPI learning technique; here, a positive torque is continuously
applied after the 28th step. There are also more instances where zero torque is applied
in both versions of fitted Q-iteration than in the policy obtained from using LSPI.
Figure 5.11: Positioning of acrobot at various steps under pi∗50 using fitted Q-iteration
with extra trees.
84 5. RESULTS AND DISCUSSION
Figure 5.12: Positioning of acrobot at various steps under pi∗50 using LSPI.
Number of steps to goal state of acrobot task for each learning technique
As in the final part of our experimentation on the mountain car domain, we compare
the average number of steps taken by each algorithm to reach the goal state from
(θ1, θ2, θ˙1, θ˙2) = (0, 0, 0, 0) under their respective optimal policies. Note that since
the acrobot task only has one terminal state i.e. when the goal state is reached, we
omit calculating the percentage of successful policies generated which we did for the
mountain car task. For this experiment, we conduct 10 trials using 10 sample sets
of 10 000 samples each. The samples are generated according to the random policy
as before. We determine the optimal policy after 50 iterations from the initial state
for each of these sets for each learning technique considered. Again, we compute the
number of steps each algorithm takes to reach the goal state from the initial state under
the optimal policies obtained. Table 5.9 shows these results.
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Trial Steps taken by NFQ Steps taken by FQI Steps taken by LSPI
1 48 39 148
2 36 35 180
3 42 42 105
4 54 27 135
5 51 29 94
6 136 80 105
7 37 31 83
8 58 32 129
9 21 48 101
10 62 37 98
Average 54.50 40.00 117.80
Table 5.9: Number of steps taken by each algorithm to reach goal state of acrobot task
under optimal policy over 10 trials.
5.3.5 Discussion of results for the swing-up acrobot domain
Results from experimentation on the swing-up acrobot control task reveal some differ-
ences in the performances of each learning technique in comparison to the results from
the mountain car task. In terms of speed, we observe once again that the extra trees
version of fitted Q-iteration is very slow. However, the speed advantage demonstrated
by LSPI when applied to the mountain car task, is not observed here. On the contrary,
there are instances where LSPI takes longer to run than fitted Q-iteration with extra
trees. This is because of the fact that a substantial number of basis functions are calcu-
lated. Ultimately, it is the method used to calculate these basis functions that largely
dictates the speed of the LSPI algorithm. Neural fitted Q-iteration is significantly faster
than both other learning techniques. In terms of the optimal policies obtained when
applying each technique to sample sets of 10 000 samples, both versions of fitted Q-
iteration have similar performance with a similar number of average steps required to
reach the goal state. LSPI takes on average double the number of steps to reach the
same goal. This is suggestive of the fact that more basis functions should possibly be
used to improve the quality of the Q-function approximation. Alternatively, it could
be worthwhile investigating the use of different basis functions, other than randomly
centered Gaussian radial basis functions, for Q-function approximation on this task.
Overall, the policy determined by the extra trees version requires the fewest steps to
reach the goal state. In doing so, the acrobot swing-up task is accomplished sooner than
when using neural fitted Q-iteration or LSPI.
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5.4 Experimentation on simulated data
In this experiment, we compare the outcomes of each batch RL algorithm when ap-
plied to HIV data simulated using the model discussed in Section 4.5.2 of the previous
chapter. In particular, we make observations about whether or not a patient’s health
status improves after taking the actions recommended by each of the learning techniques
following training.
To perform this experiment, we use an iterative data generation and testing proce-
dure analogous to Ernst et al. (2006). We assume that patients are monitored every five
days for a period of 1 000 days. At the first iteration, we generate the data for fifty pa-
tients all in the unhealthy steady state. Thereafter, every five days the patient’s health
status is assessed according to the quantities of the state variables (T1, T2, T
∗
1 , T
∗
2 , V, E)
and we select a random treatment action from the set of actions {RTI on and PI on,
RTI on and PI off, RTI off and PI on}. By recording a patient’s state of health every
five days, we obtain a trajectory (s0, a0, s1, a1, . . . , s200) corresponding to the course of
action taken on the patient over 1 000 days. This trajectory produces 200 samples of
the form (st, at, st+1). Hence, by the end of the first iteration, a total of 10 000 samples
are available. At this point we run each of the batch RL algorithms on the set of 10 000
samples for 50 iterations to produce a policy pi∗50(s0) where s0 is the unhealthy steady
start state.
During the second iterative step, we generate the data for 10 new patients again
from unhealthy stationary equilibrium and record their state data every five days for
exactly 1 000 days. Instead of randomly selecting the medication taken by a patient
every five days, we consider the optimal action suggested by the policy pi∗50 that was
obtained from the original set of 10 000 samples. We take this optimal action 70% of
the time and choose a random action for the remaining 30%. Once again we apply each
of the batch algorithms to the new set of 12 000 samples for 50 iterations and obtain a
new optimal policy for the larger sample set.
At the third iterative step, we generate the data for another set of 10 new patients
from the unhealthy steady state and record the necessary state data. We consider the
action suggested by the optimal policy obtained from the set of 12 000 samples and
take this action 85% of the time; for the remaining 15%, we choose a random action.
We repeat the iterative procedure ten times to produce a total of 30 000 samples. After
the tenth iteration, we use the optimal policy pi∗50 that was obtained from the set of
30 000 samples to generate the data for one patient (once again starting at unhealthy
stationary equilibrium). This time, we take only the action suggested by pi∗50. The
resulting trajectory obtained represents the evolution of a patient’s health condition
under the policy pi∗50 from a 30 000 sample set. We determine such a trajectory for each
of the learning methods under consideration.
By alternating between sample generation and testing using the batch RL algo-
rithms, we are able to determine whether the policies learned by the RL techniques
eventually improve a patient’s state of health overall. For the fitted Q-iteration algo-
rithm using extra trees, we build a set of 50 trees at each iteration like Ernst et al.
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(2006); for the neural fitted Q-iteration algorithm, we use a neural network with 9
input nodes corresponding to the state and action variables, 100 hidden nodes and 1
output node. When applying LSPI, we use 9 000 randomly centered Gaussian radial
basis functions with σ2 = 4.
Figure 5.16 represents the changes in the state variables for a patient being treated
from unhealthy stationary equilibrium for a period of 1 000 days following pi∗50 from using
neural fitted Q-iteration. We note that over the course of treatment an improvement in
the CD4+ count and a decrease in the overall viral load are observed. We also observe
decrease in both infected macrophages and infected T-cells with a reduced viral load.
Figure 5.13 shows the corresponding course of action taken for the patient when neural
fitted Q-iteration was applied. We observe that initially extensive drug cycling occurs
between using RTIs and PIs. This is followed by a period of using only PIs. After 730
days of treatment, the patient begins using RTIs again but this time without the use of
any PIs.
Figure 5.13: Representation of the treatment strategy, pi∗50, in terms of 1 and 2 for a
typical patient in an unhealthy steady state using neural fitted Q-iteration.
Figures 5.17 and 5.14 show these results for a patient being treated from unhealthy
stationary equilibrium for a period of 1 000 days under pi∗50 from fitted Q-iteration with
extra trees. Once again, we observe an improvement in overall health in terms of the
CD4+ count, viral load, macrophage counts and cytotoxic T-cell counts; however, the
course of action in this case involves many more periods of drug cycling than in the
previous case. Similarly, Figures 5.18 and 5.15 show the results for a patient being
treated from unhealthy stationary equilibrium for 1 000 days under pi∗50 from applying
LSPI to a set of 30 000 samples. The courses of action obtained using LSPI and fitted
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Q-iteration with extra trees are quite similar in the sense that more drug cycling occurs
with fewer periods of drug stability in comparison to the results from using neural fitted
Q-iteration. Nonetheless, all three methods allow for an improvement in a patient’s
health condition.
Figure 5.14: Representation of the treatment strategy, pi∗50, in terms of 1 and 2 for a
typical patient in an unhealthy steady state using fitted Q-iteration with extra trees.
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Figure 5.15: Representation of the treatment strategy, pi∗50, in terms of 1 and 2 for a
typical patient in an unhealthy steady state using LSPI.
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Figure 5.16: Graphs representing the evolution of state variables (T1, T2, T
∗
1 , T
∗
2 , V, E)
over 1 000 days for a patient being treated from an unhealthy steady state when applying
neural fitted Q-iteration.
5.4. EXPERIMENTATION ON SIMULATED DATA 91
Figure 5.17: Graphs representing the evolution of state variables (T1, T2, T
∗
1 , T
∗
2 , V, E)
over 1 000 days for a patient being treated from an unhealthy steady state when applying
fitted Q-iteration with extra trees.
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Figure 5.18: Graphs representing the evolution of state variables (T1, T2, T
∗
1 , T
∗
2 , V, E)
over 1 000 days for a patient being treated from an unhealthy steady state when applying
LSPI.
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5.4.1 Discussion of results from testing batch RL on simulated HIV
patient data
In general, all three methods of learning produce policies after 50 iterations that demon-
strate an improvement in the immune outcomes for an infected individual. The results
from using neural fitted Q-iteration show a more gradual change in the state variables
than the results from the other two methods. The policy obtained using neural fitted
Q-iteration has larger periods of stability where no drug cycling occurs. This seems
realistic since it allows the patient periods where they can acclimatize to using a par-
ticular drug (assuming only one drug from the particular drug class is used). However,
despite the improvement in a patient’s condition after 1 000 days, in comparison to the
results from using LSPI and fitted Q-iteration with extra trees, the overall condition
of a patient remains slightly weak. This is evident from the fact that after 1 000 days,
a patient following pi∗50 from neural fitted Q-iteration has a lower CD8+ T-cell count,
a higher infected CD4+ count and a higher infected macrophage count than a patient
following pi∗50 from LSPI and fitted Q-iteration with extra trees after the same period
of time. There is also a period within the 1 000 days where a patient under pi∗50 from
neural fitted Q-iteration experiences a blip in their viral load. This occurs after a con-
sistent decrease in their viral load between 400 and 700 days (see Figure 5.16). While
this is unlike the results obtained from applying both other learning techniques, it is
not unlike situations in real life. Often, a patient’s viral load may fluctuate despite an
improvement in their overall health status. In these situations, it is more useful to look
at other state variables as an indication of the patient’s condition. Overall, results from
using neural fitted Q-iteration suggest that using the learning technique to schedule
RTIs and PIs can result in improved patient outcomes in the simulated case. However,
within a period of 1 000 days, a patient is still unable to reach a healthy steady state.3
Similar observations can be made from the results obtained from using fitted Q-
iteration with extra trees and LSPI. In general, fitted Q-iteration with extra trees is
able to produce a policy pi∗50 that results in the largest improvement in a simulated
patient’s health status overall after a period of 1 000 days. This is evident from the
steadily decreasing infected cell counts and decreasing viral load in a patient simulated
from unhealthy stationary equilibrium. In both these cases however, drug cycling oc-
curs very frequently (see Figures 5.14 and 5.15). If this drug cycling involves switching
between classes of drugs as well as different drugs within a particular class, it is not
entirely realistic nor advisable since frequent switching can have many side-effects in
the real world. If the drug cycling involves switching between drug classes but does not
necessarily involve changing the drugs used from a particular class, this may not be the
case. In these instances, switching between drug classes would involve taking a previ-
ously used drug but from a different class. By using the model provided in Chapter 4 to
simulate patient data, it is impossible to distinguish between these cases. Other issues
that arise from using this model to simulate patient data include the fact that every
3Subsequent experimentation has shown that by extending this period to 2 000 days, a patient is
able to reach a state that is slightly closer to the healthy steady state.
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patient is simulated from the same initial state, which is not realistic. It is debatable
that the efficacy parameters for the classes of RTIs and PIs are fixed to the values of
either 0 or 0.7, and 0 or 0.3 respectively, throughout a period of treatment for each
individual. These values are specified before before performing a simulation however, in
reality we would like to determine these values to be able to ascertain which drugs are
more suitable for treatment at a particular time than others. Whether the efficacy of a
particular drug should be fixed to a particular range of values is questionable; it may
be the case that a drug’s efficacy in fact changes over time in accordance to a patient’s
infection, viral strain etc.
Ultimately, if we are to address the efficacy of frequent switching and some of the
other points raised, a more detailed mathematical model that considers variations within
each drug class, would be required. Alternatively, modelling the MDP for reinforcement
learning in a slightly different way and applying it to real data could allow us to gain
some insight about switching between individual drug types as opposed to drug classes.
All in all, the results from this experiment suggest that the model used for data sim-
ulation is too general and should incorporate more drug classes or individual drugs to
produce more telling results. For these reasons, we perform experimentation using batch
reinforcement learning techniques on real data in the next section.
5.4.2 A note about the size of the sample set used for simulated data
testing
In this experiment we have used a large sample set consisting of the data from several
patients. This is motivated by the fact that using a larger sample set of more patients
allows for more opportunities for variation to exist between samples. This variation
is especially interesting for the purposes of learning and is reasonably important if we
consider the fact that the model for data simulation uses only three actions. However, in
reality it is possible that a significantly smaller sample of the population is available as a
result of restricted data sources. For these purposes, it may also be worth investigating
how the learning techniques perform on a significantly smaller sample set to be able
to make a fair comparison between performances on both real and simulated data sets.
The results of this experiment may be found in Appendix B.
5.5 Experimentation on real patient data
In this section, we extend our experimentation using batch reinforcement learning tech-
niques further to a real HIV data setting. Unlike the sets of generated HIV data used
in the previous section, real HIV data does not conform to a specific model and behaves
significantly more unpredictably.
As described in Section 4.6.2 of Chapter 4, using real data introduces a number of
issues that need to be carefully considered. In addition, the application of batch RL
techniques to real data requires a different MDP formulation. For this experiment, we
make use of our complete set of HIV data consisting of data from 250 random HIV-
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infected individuals corresponding to 2 560 samples. The data has been preprocessed
and prepared according to the discussion in Section 4.6.2. This is smaller than the
data sets used in all previous experimentation based on our limited access to real data
sources.
The outcome of this experiment corresponds to one or more action(s) in terms of
drug therapy that the patient can take at a certain time step. Since we have no way of
implementing these actions in real life, it is impossible to predict what will happen to
the patient as a result of the action and use this information to determine subsequent
actions. Hence for this experiment, we perform a ten-fold cross validation test in which
the actions suggested by the learning techniques for a certain sample are validated
against those actions or drugs used by the individual at that particular time. While
this does not necessarily guarantee the best course of treatment, it allow us to determine
the number of times the outcomes of the algorithm are consistent with the treatments
followed by doctors.
In particular, we divide our data into ten validation and training sets respectively.
Validation sets are constructed by selecting 256 samples from the original sample set and
using the remaining samples as corresponding training data for an individual test. That
is, we partition the sample set into ten sets of size 256 samples each. For a single trial,
we use one of the sets as validation data while training on the remaining 2 304 samples
comprising the other sets. The process is repeated over ten trials, each time using a
different set of 256 samples to validate against. Training sets are used to train the
batch algorithms while validation sets are used for purposes of measuring the number of
times a match occurs between the outcomes of a particular learning technique following
training, and the current course of treatment for a patient. The results are averaged over
the ten sets to produce the average number of matches that occur under each learning
method. Using ten-fold cross validation is advantageous since it allows for the possibility
of selecting each individual sample from the original set once for testing. We note it is
possible that the learning techniques suggest more than one suitable action. Here, the
approximate Q-values for these actions is the same. In these cases, if a match occurs
between one of the suggested actions and the originally prescribed action, we regard
this as a successful match. While using matching accuracy as a performance measure
assumes a symmetric loss in getting a prescription wrong which is most certainly not the
case in reality, the results from using these learning algorithms are intended to serve as
clinical-decision support, rather than a means of automating decision-making in clinical
practice.
We have performed this experiment using M = 50 and nmin = 2 for fitted Q-iteration
with extra trees, however preliminary testing revealed similar results when using larger
values of M for this domain. Using neural fitted Q-iteration required us to construct
a much larger neural network for training and testing purposes. Specifically, we use
9 input nodes (corresponding to the two state variables and seven dimensional binary
actions), 350 hidden nodes in the first hidden layer, 300 hidden nodes in the second
hidden layer and 1 output node corresponding to the Q-value of a particular state-
action pair (s, a). For LSPI, we use 2 560 randomly centered Gaussian radial basis
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functions with σ2 = 2. We have run 50 iterations of each learning technique for training
purposes. We present our results for each validation set in Table 5.10.
Trial Matches using NFQ Matches using FQI Matches using LSPI
1 190 211 203
2 181 209 174
3 213 199 192
4 220 174 227
5 96 158 145
6 179 191 198
7 102 111 82
8 203 207 141
9 194 194 215
10 178 143 86
Average 175.60 179.7 166.30
% consistency 68.60 70.20 64.96
Table 5.10: Average consistency between learned actions and actions taken by clinicians
using FQI with extra trees, NFQ and LSPI respectively.
5.5.1 Discussion of results in a real HIV setting
Results from this experiment have demonstrated that batch reinforcement learning tech-
niques can be applied to real HIV data with reasonable success. We observe that despite
the use of a relatively straightforward reward function and a state space consisting of
only two state variables, all three learning techniques are able to produce outcomes that
are consistent with the actions prescribed by clinicians a large number of times. This is
quite interesting since medical professionals usually perform a number of different tests
to assess a patient’s health before prescribing a particular treatment. The information
gained from these assessments is vastly more specific than what we use to train the
learning methods for this experiment. On average, fitted Q-iteration with extremely
randomized trees produces an outcome that matches the action taken by a clinician
most frequently. The results from performing the same experiment using neural fitted
Q-iteration and LSPI are fairly similar but less successful.
It is evident that choosing drugs for a patient involves considering their health status.
This is dictated by time. That is, it may be reasonable to take certain combinations of
drugs at one particular point in time but not at another. For these reasons, it is not
necessarily the case that drugs that are used frequently among most patients are the
best choice for every infected individual. This means that we cannot use the frequency
at which a particular drug combination is suggested by the learning methods as an
overall indicator of the quality of learning. We can however, compare the combinations
of drugs recommended to those commonly used in treating HIV to see how realistic the
learning is in terms of the suggested actions.
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In this particular experiment, the most frequently occurring combination of drugs
suggested by FQI with extra trees is EFV, 3TC, tdf. This is perfectly reasonable given
the data used for training the algorithm and the fact that this combination is one that is
regularly prescribed by medical professionals to HIV-infected individuals. Consider the
validation set used in trial 5 in Table 5.10. This set of data produces a poor number of
matches when used with neural fitted Q-iteration. Figure 5.19 shows the frequency at
which combinations of actions are recommended. Figure 5.20 shows the actual frequency
of drug combinations used in the same validation set. It is evident that the results
are vastly different which ultimately means that a poor number of matches occur. It
is obvious that neural fitted Q-iteration does not identify all the drug combinations
prescribed for the data set. In particular, the NFQ algorithm fails to suggest the most
frequently used drug combination for this validation set - AZT, tdf, LPV/r. One possible
explanation for this is that having extracted the data used in this validation set from the
original sample set, there are not enough samples using this action in the training set.
There is only one instance where the action prescribed almost certainly produces a match
using NFQ. This occurs when using the 3TC, LPV/r combination. NFQ suggests using
this action 23 times in the validation set; in reality, this action was prescribed 20 times.
It is also possible that there may be more than one suitable action available to a clinician
at a particular time which could account for the number of mismatches that occur here.
Based on the smaller number of matches that occur when using NFQ and LSPI on the
validation set in trial 5, one would presume that the combinations of drugs suggested
by these methods are not standard. However, this is certainly not the case. Instead,
the actions that are suggested are not unusual in terms of the combinations of drugs
used in reality. Most combinations of drugs are not recommended at all (demonstrated
by the gaps between actions that are selected in Figure 5.19). We observe that the
most frequently occurring drug combination suggested by neural fitted Q-iteration is
EFV, 3TC, d4T. This is a standard drug combination that is prescribed 21 times in
the validation set used for trial 5. Similar results are observed in the other validation
sets where matching is poor too. Despite observing a poor number of matches in these
validation sets, the actions recommended by the learning techniques are realistic in
comparison with the drug combinations typically used by doctors every day. This is
extremely promising if we are to consider using RL techniques in treatment design in the
future. From the perspective of treatment simplification, these combinations of drugs
may be suitable candidates for re-formulation to reduce patient pill burden and improve
adherence to medication.
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Figure 5.19: Frequency of recommended drug combinations when applying neural fitted
Q-iteration to the validation set used for trial 5.
We have used a fairly sparse set of HIV samples to train and test each of the learning
techniques in this thesis. For this reason, it may be more practical to perform leave-
one-out cross validation instead of ten-fold cross validation in order to train the learning
methods using as many samples as possible. It may also be interesting to train using all 2
560 samples and observe the outcomes produced when testing using samples comprising
the actual training set. We have done this and tested the outcomes on the samples that
comprised the validation set used in trial 1 previously. In this case, FQI using extra
trees produces a match 219 times; NFQ produces a match still only 190 times, and
LSPI produces a match 211 times. While one would expect the number of matches to be
improved by training using more samples and testing on samples comprising the training
set, the improvement is only a slight one. In fact, the number of matches produced by
NFQ is identical to when the validation data was separated from the original set of
samples in trial 1. This is very interesting since it suggests the performances of the
learning methods from training using a complete sample set are very similar to the
performances from training using a partial sample set. Perhaps this is indicative of the
fact that to observe an improvement in the number of matches, a significantly larger set
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of samples is required. Alternatively, it suggests that better neural network structures
or basis functions should be considered in NFQ and LSPI to improve training. It is
also possible that the parameters used in FQI with extra trees could be better tuned to
produce an improved number of matches.
Figure 5.20: Frequency of prescribed drug combinations in the validation set used for
trial 5.
5.5.2 A note about supervised learning
A natural question that arises after investigating the use of batch RL techniques to
identify suitable treatments for HIV-infected individuals at specific times, is whether or
not using supervised learning techniques alone would be able to produce similar results.
To investigate this, we consider comparing the outcomes produced by a standard neural
network with those produced by the reinforcement learning techniques under consid-
eration. Here, our neural network is structured to take as input a patient’s wellness
indicators in the form of a log-normalized CD4+ count and viral load. The output of
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the neural network corresponds to the action identified as a suitable treatment for a
patient for a particular sample. Hence our neural network structure consists of 2 input
nodes, one hidden layer with 300 nodes and an output layer of 7 nodes. These 7 nodes
correspond to whether a particular drug is selected for treatment or not. In this experi-
ment, we use the data that was used for validation in trial 1 of the previous experiment
as test data, and observe the number of times the output of the network corresponds
to a match in treatment. That is, we consider the 256 samples used in trial 1 of our
real data experimentation as test data for the neural network. The remaining 2 304
samples are used for training the neural network. We train the neural network using
the resilient backpropagation technique that was also used for neural fitted Q-iteration
for 20 000 epochs. We observe that the neural network produces an outcome that is
consistent with prescribed treatments only 82 times. This corresponds to a matching
accuracy of 32%. Similar results are obtained when using the data from trials 2 - 10
from the previous experiment as test data. These results are shown in Table 5.11. There
are also a few cases where the neural network produces a single drug as output. This is
unusual as most HIV-infected individuals are prescribed combinations of antiretrovirals
to prevent the development of drug-resistant HIV strains.
Trial Matches using an artificial neural network
1 82
2 97
3 64
4 75
5 79
6 78
7 94
8 62
9 64
10 86
Average 78.1
% consistency 30.51
Table 5.11: Average consistency between learned actions and actions taken by clinicians
using neural networks alone.
Upon closer investigation, a number of comparisons can be made between using su-
pervised learning alone and using RL methods. Perhaps the most interesting of these
comparisons arises when we examine the case where a patient suddenly transitions from
a very good state of health to a very bad one or vice versa. Consider the specific exam-
ple of a patient with a CD4+ count of 350 cells/mm3 and a viral load of 40 copies/ml
currently being treated with EFV and 3TC. The patient’s condition under this treat-
ment deteriorates rapidly resulting in a new CD4+ count of 120 cells/mm3 and a viral
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load of 310 064 copies/ml.4 At this point the the patient’s treatment is altered to a new
combination of drugs 3TC, tdf and NVP. The fact that a patient’s treatment is altered
at this point is not unusual as the viral load changes from being virtually undetectable
to being reasonably high. While it is not always the case, a change of this magnitude
in the viral load, is usually the first indication that a patient is developing drug resis-
tance to one or more of the prescribed drugs.5 Because there are several examples in
the training data where a patient is under the treatment of EFV and 3TC, the neural
network method is able to detect this and hence suggests using the same combination
of drugs that was initially prescribed, as opposed to switching to the new combination
of drugs prescribed. The same patient is suggested a combination of 3TC, tdf and d4T
when using neural fitted Q-iteration and fitted Q-iteration with extra trees, while we
observe an exact match in the treatment suggested by LSPI. Similar results can be seen
when dealing with longer patient trajectories. This example highlights a key difference
between classical supervised learning techniques and RL methods for HIV drug schedul-
ing: supervised learning methods have no way of identifying what happens to a patient
after taking a particular course of action since each sample of data is treated separately
without any reference to another. Conversely, RL methods use state and subsequent
state information to learn the value of making a particular transition between these
states. This is crucial since a patient’s history may be embedded into their state infor-
mation. The fact that RL methods make use of a long-term horizon means that at each
iteration of the learning techniques, we can look further and further into the future to
choose actions appropriately. This is a crucial piece of information as an action that is
beneficial in the immediate future may not necessarily be beneficial in the long run. It is
not possible to make such an assessment using standard supervised learning techniques.
5.6 Discussion in relation to research questions
Having completed experimentation, we can now answer the research questions posed in
Section 4.3 of Chapter 4.
1. It is possible to model the problem of HIV drug scheduling in terms of an MDP
where the state space S is comprised of variables that serve as indicators of a
patient’s health at a particular time. In this research, we have chosen CD4+ T-
lymphocyte counts and viral loads as our variables however, it is also possible to
extend the state space to include several other wellness indicators. The action
space A consists of the drugs used to treat a patient at a particular time. We
have constructed a seven-tuple indicating whether the drugs EFV, 3TC, d4T,
TDF, NVP, LPV/r and AZT are at use at a certain time in treatment. Like
the state space, these drugs may be exchanged for other drugs. The inclusion of
newly developed drugs into the action space would require the dimensionality of
4These are the values of the state variables without normalization.
5At this point a doctor may choose to run one or more drug resistance tests to ascertain whether
such resistance exists.
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the action vector to be increased. The introduction of more state variables to the
MDP may mean that features must be extracted from the set of data first before
applying the batch algorithms to these features.6 Alternatively, dimensionality
reduction techniques could be applied to the state space if necessary. A reward
function for this MDP is based on rewarding those instances where actions result
in improved T-cell counts or lowered viral loads and penalizing those that do not.
2. The performances of the learning techniques vary when applied to the problem
of determining suitable drug combinations for a real patient. By performing ten-
fold cross validation on sets of patient data, we observe that all three learning
methods are capable of producing outcomes that are consistent with strategies
that are currently in place. Fitted Q-iteration using extremely randomized trees
produces these outcomes the most frequently in comparison to the other two
learning methods. However, strategies to improve overall learning among all three
methods can be introduced. All three learning methods demonstrate the ability
to suggest drug combinations that are not unusual and are commonly used in the
real world. This highlights their potential to be coupled with clinical research to
enhance treatment design.
3. When we apply the learning techniques to simulated patient data, we observe that
all three methods are successful at improving patient wellness. The strategies
determined by LSPI and fitted Q-iteration using extra trees are fairly similar as
opposed to the strategy determined using neural fitted Q-iteration. Despite the
overall improvement observed, the strategies determined by LSPI and fitted Q-
iteration involve a lot of switching between using RTIs and PIs with few periods
of stability. This may not be feasible since frequent switching can have adverse
effects on real patients. Overall, the model used to simulate patient data is too
general in terms of the actions it considers, and would need to be modified to
include more drugs or classes of drugs for more meaningful results.
4. The batch RL techniques considered in this research have demonstrated good per-
formance, in general, when applied to the benchmark domains. All three methods
are able to produce optimal policies that succeed in reaching the goal state for
the mountain car task. Experimentation on the acrobot task demonstrated the
performances of the learning methods in a higher-dimensional state space. Re-
sults revealed similar performance between both versions of fitted Q-iteration. In
terms of speed, the extra trees implementation is very slow. The speeds of the
other learning methods vary with the size of neural network and number of basis
functions used. For large data sets, it may be worth considering using better hard-
ware to run these learning methods on. The use of benchmark domains in this
research has not only helped compare the batch RL techniques on relatively well-
behaved data sets, but also allowed us to gain a better understanding of learning
in continuous state spaces.
6The interested reader should refer to Lange et al. (2012) for these details.
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5.7 Conclusion
This chapter presented the major results of this research. Results reveal that batch
reinforcement learning methods vary in their performances across different domains.
For the case of simulated data, all three methods have shown the ability to improve
a patient’s outcomes by scheduling appropriate drug use. In a real medical setting,
results suggest that batch learning methods have the potential of assisting clinicians
in decision-making however, more testing using larger data sets and inclusion of more
state and action variables is recommended.
Chapter 6
Conclusions and Future Work
Discovering effective treatment strategies for HIV-infected individuals remains one of
the main challenges in medical research. Existing treatments combine anti-HIV drugs
under HAART to inhibit the development of drug-resistant HIV strains. Despite the
fact that eradicating the virus using HAART may not be possible, improved strategies
for choosing suitable drug combinations and scheduling drugs are necessary for better
control of viral infection. Such strategies may also enable treatments to be simplified,
and drug combinations to be re-formulated to reduce a patient’s pill burden and improve
adherence to medication.
In this dissertation, we have demonstrated the application of batch reinforcement
learning to the problem of drug scheduling and HIV treatment design. Specifically, we
have used the techniques of fitted Q-iteration with extremely randomized trees, neu-
ral fitted Q-iteration and LSPI to address this problem. In particular, we have shown
that it is possible to formulate the problem of HIV drug scheduling as an MDP by
using a patient’s wellness indicators as state variables and considering drug combina-
tions as actions. Results from experimentation on real data suggest that each learning
technique has its associated benefits and disadvantages. However, all three techniques
have the potential of suggesting drug combinations that are reasonably consistent with
those prescribed by medical professionals for HIV patients. The implications of this are
tremendous: overall, these techniques could be coupled with the expertise of clinicians
to improve treatment design.
We have also addressed the research questions formulated in Chapter 4. The perfor-
mances of all three batch reinforcement learning techniques were recorded and compared
when applied to the benchmark domains of mountain car and swing-up acrobot. Re-
sults demonstrate varied performance among all three techniques in terms of speed and
the quality of solutions produced. Testing these methods using simulated HIV data re-
vealed that all the techniques were suitable in determining drug strategies that improve
the health status of an infected individual however, limitations in the model used for
simulation mean that the strategies determined are not entirely realistic nor practical.
This research opens many avenues for future work. From a theoretical perspective,
it would be worth investigating the use of a more complex reward function that takes
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into account variations or perhaps smaller differences in the state variables. It would
also be worth looking into using more basis functions for the LSPI technique or improve
basis function selection in general. The inclusion of more suitable basis functions could
allow for better function approximation particularly when applying LSPI to real data.
Similar improvements could be made to neural fitted Q-iteration by considering changes
to the neural networks used for training.
From a practical perspective, HIV is a virus that invades and infects the body
using a number of mechanisms. Each of these mechanisms involves a series of complex
interactions between several biological components of the immune system. Furthermore,
an individual’s response to HIV is dictated by a number of factors such as cytokine
production, the presence of other infections and whether there is repeated exposure to
the virus. For these reasons, perhaps the biggest avenue for future research in this area
involves extending the MDP we have used here to include many more state variables
such as complete white blood cell counts, HIV strain information, information about
the occurrence of other infections such as tuberculosis, and even variables that take
into account differences between individuals such as age, sex, etc. These differences
may play an important role in explaining why some individuals have better responses
to viral infection than others. It is more than likely that including more variables would
improve quality of learning overall. We have only considered the use of seven major
drugs for the treatment of HIV however, the same techniques can be applied to the
complete list of HIV drugs, if larger data sets using each of these drugs are available.
Finally, we have shown the potential for batch reinforcement learning techniques to
be used for improving treatments for people suffering from HIV, largely because of its
prevalence in South Africa. These techniques, if used in a clinical trial setting, could
provide insight into the combinations of drugs that are suitable for these individuals and
identify candidates of drugs for treatment simplification. However, the application of
these techniques to other medical domains such as treatment of epilepsy, types of cancers
or other life-threatening illnesses is also possible, and may prove incredibly useful for
treatment design.
Appendix A
Benchmark Domains
A.1 The Acrobot Swing-Up Control Problem
The dynamics of the acrobot swing-up control problem may be described by the system
of Equations A.1.1. In particular, the robot arm contains two links: the first rotates
freely about the joint whilst the second is actuated by a torque applied to the joint.
The state space can be described in terms of the four continuous state variables, θ1, θ2,
θ˙1 and θ˙2 where θ1 is the angular position of the first link in relation to the joint, and
θ2 is the angular position of the second link in relation to the first; θ˙1 and θ˙2 are the
angular velocities of each link respectively. A reward of -1 is given at each time step,
t = 0.05, until the goal is reached.
θ¨1 = −d1−1(d2θ¨2 + φ1) (A.1.1)
θ¨2 =
(
m2l
2
c2 + I2 −
d22
d1
)−1(
τ +
d2
d1
φ1 − φ2
)
d1 = m1l
2
c1 +m2
(
l21 + l
2
c2 + 2l1lc2 cos θ2
)
+ I1 + I2
d2 = m2
(
l2c2 + l1lc2 cos θ2
)
+ I2
φ1 = −m2l1lc2θ22 sin θ2 − 2m2l1lc2θ˙2θ˙1 sin θ2 + (m1lc1 +m2l1) g cos (θ1 − pi/2) + φ2
φ2 = m2lc2g cos (θ1 + θ2 − pi/2)
Here g = 9.8 is the gravitational force. The joint positions θ1 and θ2 can take any value;
the angular velocities θ˙1 and θ˙2 are restricted to [−4pi; 4pi] and [−9pi; 9pi] respectively.
The rest of the parameters are described in Table A.1
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Parameter Description of parameter Value
m1, m2 masses of links 1.0
l1, l2 lengths of links 1.0
lc1, lc2 lengths to mass centre 0.5
I1, I2 link inertias 1.0
τ torque {-1.0, 0.0, 1.0}
Table A.1: Parameters of the swing-up acrobot control problem.
A.2 Mountain Car
The mountain car system dynamics can be expressed in terms of the following set of
equations (directly as in Ernst et al. (2005)):
dp
dt
= v (A.2.1)
dv
dt
=
a
m+Hill′(p)2
− gHill
′(p)
1 +Hill′(p)2
− v
2Hill′(p)Hill′′(p)
1 +Hill′(p)2
.
Here m = 1, g = 9.81 and the function Hill(p) is defined as:
Hill(p) =
{
p2 + p p < 0
p√
1+5p2
p ≥ 0 (A.2.2)
For simulation purposes we choose t = 0.1s and generate sample sets using Euler’s
method with 0.001s as an integration step.
Appendix B
Additional Results
B.1 Experimentation using a set of simulated HIV data of
a smaller size
This appendix presents the results from using smaller sample sets of simulated data
for learning. As in Section 5.4 of Chapter 5, we compare the outcomes of each learn-
ing algorithm when applied to HIV data simulated using the model in Section 4.5.2
in Chapter 4. We are particularly interested in whether performance of the learning
methods degrades as a result of using a smaller set of samples for learning.
To perform this experiment, we use an iterative data generation and testing proce-
dure virtually identical to the experimentation in Section 5.4. Once again we assume
that patients are monitored every five days for a period of 1 000 days. At the first iter-
ation, we generate the data for two patients in the unhealthy steady state. Thereafter,
we record the status of each patient’s health every five days according to the quanti-
ties of the state variables (T1, T2, T
∗
1 , T
∗
2 , V, E). At each time step, we select a random
treatment action from the set of actions {RTI on and PI on, RTI on and PI off, RTI off
and PI on}. From this, we obtain a trajectory (s0, a0, s1, a1, . . . , s200) corresponding to
the course of action taken on the patient over 1 000 days. This trajectory produces 200
samples of the form (st, at, st+1). Hence, by the end of the first iteration, a total of 400
samples are available. At this point we run each of the batch RL algorithms on the set
of 400 samples for 50 iterations to produce a policy pi∗50(s0) where s0 is the unhealthy
steady start state.
At the second iterative step, we generate the data for two new patients, again from
the unhealthy steady state. We once again record their state data every five days for
1 000 days. Instead of randomly selecting the medication taken by a patient every five
days, we consider the optimal action suggested by the policy pi∗50 that was obtained
from the original set of 400 samples. We take this optimal action 70% of the time and
choose a random action for the remaining 30%. Once again we apply each of the batch
algorithms to the new set of 400 samples for 50 iterations and obtain a new optimal
policy for the larger sample set.
At the third iterative step, we generate the data for another two new patients from
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the unhealthy steady state and record the necessary state data. We consider the action
suggested by the optimal policy obtained from the set of 600 samples and take this action
85% of the time; for the remaining 15%, we choose a random action. We repeat this
procedure of training on the sample set, determining an optimal policy and using this
policy to generate the data of 2 new patients (whose data is added to the original sample
set) five times. After the fifth iteration, we use the optimal policy pi∗50 that was obtained
from the set of 2 000 samples to generate the data for one patient (once again starting at
unhealthy stationary equilibrium). This time, we take only the action suggested by pi∗50.
The resulting trajectory obtained represents the evolution of a patient’s health condition
under the policy pi∗50 from a 2 000 sample set. We determine such a trajectory for each
of the learning methods under consideration. For the fitted Q-iteration algorithm using
extra trees, we build a set of 50 trees at each iteration like Ernst et al. (2006); for
the neural fitted Q-iteration algorithm, we use a neural network with 9 input nodes
corresponding to the state and action variables, 100 hidden nodes and 1 output node.
When applying LSPI, we use 9 000 randomly centered Gaussian radial basis functions
with σ2 = 4 as before.
Figure B.1: Representation of the treatment strategy, pi∗50, in terms of 1 and 2 for a
typical patient in an unhealthy steady state using neural fitted Q-iteration with |F| =
2 000 samples.
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Figure B.2: Representation of the treatment strategy, pi∗50, in terms of 1 and 2 for a
typical patient in an unhealthy steady state using fitted Q-iteration with extra trees
where |F| = 2 000 samples.
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Figure B.3: Representation of the treatment strategy, pi∗50, in terms of 1 and 2 for a
typical patient in an unhealthy steady state using LSPI and |F| = 2 000 samples.
Figures B.4, B.5 and B.6 represent the changes in the state variables for a patient being
treated from unhealthy stationary equilibrium for a period of 1 000 days following pi∗50
using neural fitted Q-iteration, fitted Q-iteration with extra trees and LSPI respectively.
The corresponding courses of action under each learning method are provided in Figures
B.1, B.2 and B.3 respectively.
Overall, the results from using a smaller sample set for learning are fairly similar to
those results produced from using a significantly larger set of samples as in Chapter 5.
This probably serves as evidence that there are many repetitions in the larger sample
set used for experimentation in Section 5.4, as a result of a small action space. We still
observe an improvement in the overall health of a patient in terms of the CD4+ count,
viral load, macrophage counts and cytotoxic T-cell counts across all three learning
techniques. However, the courses of action suggested by each learning method are
significantly less erratic. While these sort of treatment strategies are certainly more
realistic, this may also be a direct result of using fewer samples with less variation
between them.
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Figure B.4: Graphs representing the evolution of state variables (T1, T2, T
∗
1 , T
∗
2 , V, E)
over 1 000 days for a patient being treated from an unhealthy steady state when applying
neural fitted Q-iteration across a smaller sample set of |F| = 2 000 samples.
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Figure B.5: Graphs representing the evolution of state variables (T1, T2, T
∗
1 , T
∗
2 , V, E)
over 1 000 days for a patient being treated from an unhealthy steady state when applying
fitted Q-iteration with extra trees across a smaller sample set of |F| = 2 000 samples.
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Figure B.6: Graphs representing the evolution of state variables (T1, T2, T
∗
1 , T
∗
2 , V, E)
over 1 000 days for a patient being treated from an unhealthy steady state when applying
LSPI across a smaller sample set of |F| = 2 000 samples.
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